USRE39007E1 - Isothermal strand displacement nucleic acid amplification - Google Patents
Isothermal strand displacement nucleic acid amplification Download PDFInfo
- Publication number
- USRE39007E1 USRE39007E1 US10/164,833 US16483302A USRE39007E US RE39007 E1 USRE39007 E1 US RE39007E1 US 16483302 A US16483302 A US 16483302A US RE39007 E USRE39007 E US RE39007E
- Authority
- US
- United States
- Prior art keywords
- nucleic acid
- complementary
- sequence
- primer
- primers
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6844—Nucleic acid amplification reactions
Definitions
- This invention relates to methods for amplifying nucleic acid sequences without thermal cycling.
- This invention concerns diagnostic procedures and tech- niques for amplifying a nucleic acid sequence.
- the detection and quantitation of a specific nucleic acid sequence is an increasingly important technique having numerous applications including identifying and classifying microorganisms, diagnosing infectious diseases, detecting and characterizing genetic abnormalities, identi- fying genetic changes associated with cancer, studying genetic susceptibility to disease, measuring the response to various types of treatment, identifying criminal suspects, and resolving paternity disputes.
- Nucleic acid hybridization typically, uses a labeled nucleic acid probe having a nucleic acid sequence complementary to the target sequence.
- the probe is mixed with a sample suspected of containing the target sequence under conditions suitable for hybrid formation.
- the probe then hybridizes to the target sequence present in the sample.
- Hybridization can be detected by various techniques well known in the art. These techniques include selectively degrading the label present on unhybridized probe and then measuring the amount of label associated with the remaining hybridized probe (Arnold et al., PCT US88/02746).
- nucleic acid polymers Numerous methods are available for amplifying nucleic acid strands (i.e., nucleic acid polymers) to increase the amount of target sequence. These methods use the nucleic acid strand containing the target sequence as a template to produce a complementary nucleic acid strand containing the target sequence. Such methods include the polymerase chain reaction method (PCR), as described by Mullis et al., (See U.S. Pat. Nos. 4,683,195, 4,683,202, and 4,800,159 and European Patent Application Nos. 863022-98.4, 86302299.2, and 87300203.4, and Methods in Enzymology, Volume 155, 1987, pp. 335-350).
- PCR polymerase chain reaction method
- PCR involves the use of a pair of specific oligonucleotides as primers for the two complementary strands of the double-stranded DNA con- taining the target sequence.
- the primers are chosen to hybridize at the ends of each of the complementary target strands, 3′ of the target sequence.
- Template-dependent DNA synthesis, on each strand can then be catalyzed using a thermostable DNA polymerase in the presence of the appro- priate reagents.
- a thermal cycling process is required to form specific hybrids prior to synthesis and then denature the double stranded nucleic acid formed by synthesis. Repeating the cycling process geometrically amplifies the target sequence.
- a PCR method may also be used with an RNA target using RNA-dependent DNA polymerase to create a DNA template.
- the PCR method has been coupled to RNA transcription by incorporating a promoter sequence into one of the primers used in the PCR reaction and then, after amplifica- tion by the PCR method, using the double-stranded DNA as a template for the transcription of single-stranded RNA (See, e.g., Murakawa et al., DNA 7:287-295 (1988)).
- Other amplification methods use multiple cycles of RNA-directed DNA synthesis and transcription to amplify DNA or RNA targets (See, e.g., Burg et al., WO 89/1050; Gingeras et al., WO 88/10315 (sometimes called transcription amplification system or TAS); Kacian and Fultz, EPO Application No.
- Urdea, W091/ 10746 describe a method that achieves signal amplification using a T7 promoter sequence.
- LCR ligase chain reaction
- European Patent Publication 320,308 The ligase chain reaction (LCR) is described in European Patent Publication 320,308. This method requires at least four separate oligonucleotides, two of which hybridize to the same nucleic acid template so their respective 3′ and 5′ ends are juxtaposed for ligation. The hybridized oligonucleotides are then ligated forming a complementary strand on the nucleic acid template. The double-stranded nucleic acid is then denatured, and the third and fourth oligonucleotides are hybridized with the first and second oligonucleotides that were joined together. The third and fourth oligonucleotides are then ligated together. Amplification is achieved by further cycles of hybridization, ligation, and denaturation.
- the palindromic probe forms a hairpin with a nucleic acid target sequence.
- the probe contains a functional promoter located in the hairpin region from which RNA transcripts are produced.
- Becker, et al., EPO Application No. 88306717.5 describe an amplification method in which a primer is hybridized to a nucleic acid sequence and the resulting duplex cleaved prior to the extension reaction and amplification.
- RPA Random Priming Amplifi- cation
- the present invention features methods for amplifying target nucleic acid sequences using a nucleic acid poly- merase lacking 5′ exonuclease activity and oligonucleotide primers.
- the method of the present invention may be performed using a nucleic acid polymerase having 5′ exonuclease activity if the oligonucleotide primers have a 5′ modification which prevents or reduces nucleolytic diges- tion of the primers.
- amplification is carried out using a primer array comprising two sets of primers. One set contains at least two primers complementary to the target nucleic acid. The other set contains at least two primers of the same sense as the target nucleic acid.
- amplification can be carried out under essentially constant environmental conditions without the requirement for exonuclease activity or restriction endonuclease activity.
- amplification is carried out using a DNA template, and a DNA polymerase such as a modified Bacil- lus stearothermophilus (Bst) DNA polymerase which lacks 5′ exonuclease activity.
- a DNA polymerase such as a modified Bacil- lus stearothermophilus (Bst) DNA polymerase which lacks 5′ exonuclease activity.
- oligonucleotide members of each primer set are used as initiation points for template-dependent synthesis of a complementary nucleic acid strand, and to enhance displace- ment of the synthesized complementary strand.
- strand displacement and nucleic acid synthesis are carried out in one step. This is a surprising finding, and Applicant is unclear of the exact mechanism by which the procedure operates.
- a primer array is preferably used to amplify both the initial template and its complement to exponentially amplify a target sequence.
- the nucleic acid polymerase lacks 5′ exonu- clease activity, and the procedure is performed at higher temperatures than those at which enzymes such as the Klenow fragment of E. coli DNA polymerase I are optimally active.
- the reaction is more efficient at 43° C. than at 37° C. Optimal efficiency is obtained at temperatures between 50° C. and 70° C.
- the method is preferably used on DNA.
- An RNA target sequence is preferably amplified by first creating a DNA copy using, for example, reverse transcriptase. The DNA copy is then amplified by the methods described herein.
- the present invention should be able to directly amplify an RNA sequence using an enzyme able to synthe- size an RNA complementary strand on an RNA template.
- an enzyme preferably lacks 5′ exonuclease activity.
- QB replicase used in conjunction with manganese should be suitable for this purpose.
- the invention features a method for amplifying a target nucleic acid sequence by contacting a nucleic acid strand containing the target sequence with a nucleic acid polymerase lacking 5′ exonuclease activity (5′-exo-minus polymerase), four different nucleotides, and at least two complementary oligonucleotide primers.
- a nucleic acid polymerase lacking 5′ exonuclease activity 5′-exo-minus polymerase
- four different nucleotides Preferably, four different deoxynucleotides and/or three of more primers are used.
- the amplification is carried out under primer extension conditions at essentially constant temperature.
- amplification is carried out using a nucleic acid polymerase that has 5′ exonuclease activity but under conditions wherein such activity is inhibited, and amplification is carried out using at least two complemen- tary oligonucleotide primers in the absence of a restriction endonuclease active on the products of any extension reac- tion of said contacting step.
- the invention features a method for amplifying a target nucleic acid sequence by contacting a nucleic acid strand containing the target sequence with a nucleic acid polymerase lacking 5′ exonuclease activity (5′-exo-minus polymerase), four different nucleotides, at least two complementary oligonucleotide primers, and at least two sense primers.
- the amplification is carried out under primer extension conditions at essentially constant temperature.
- the total number of complementary primers and sense primers is more than 5.
- the nucleic acid strand present prior to amplification serves as an initial nucleic acid template for the synthesis of a complementary strand containing the target sequence.
- the complementary strand can act as a nucleic acid template to produce strands analogous to the initial nucleic acid tem- plate.
- the analogous strands can act as nucleic acid tem- plates.
- the resulting amplification of target sequence is geometric.
- Primer extension conditions refer to conditions wherein template-dependent amplification initiated at an oligonucle- otide primer can occur. Such conditions generally include provision of an appropriate buffer and, optionally, other chemicals that may stabilize the polymerase, or enhance primer extension reactions.
- Tempolate refers to a nucleic acid strand, such as DNA or RNA, which can serve as a substrate for the synthesis of a complementary nucleic acid strand.
- target sequence refers to a specific nucleic acid sequence contained on a single strand of an oligonucleotide or nucleic acid molecule, or the nucleic acid sequence complementary thereto.
- a “complementary primer” refers to an oligonucleotide primer having a nucleic acid sequence complementary to a nucleic acid sequence present on the nucleic acid template.
- Complementary primers are designed to be complementary to nucleic acid sequences, on the nucleic acid template, in regions 3′ to the target sequence.
- oligonucleotide primer can hybridize to a region of the nucleic acid template under the conditions of the contacting step so it can be extended in a primer extension reaction.
- oligonucleotides have a region of complementarity to the template of between 15 and 100 bases, preferably between about 20 and 50 bases.
- the region of complemen- tarity is 100% complementary. That is, each nucleotide in the primer complementary region can hydrogen bond with a nucleotide present on the single-stranded template.
- primers having a complementary region less than 100% complementary to the template will operate in this method.
- complementarity can be as few as 15 out of 18 contiguous bases.
- a “sense primer” refers to an oligonucleotide analogous to a nucleic acid sequence present on the nucleic acid template.
- a sense primer is designed to be analogous to a region on the template 5′ of the target sequence.
- analogous is meant that the oligonucleotide has essentially the same, or equivalent, nucleotide sequence as that in the nucleic acid template.
- the oligonucleotide may contain uracil in place of a thymine present in the nucleic acid template.
- the analogous oligo- nucleotides are preferably sufficiently duplicative of the template so they can act as a complementary primer when hybridized to a nucleic acid that is complementary to the nucleic acid template, under primer extension conditions.
- complementary primers and sense primers are made with respect to a particular template.
- the same primer can act as a complementary primer or a sense primer depending upon whether it is analogous to, or complementary to, a particular template.
- Primer-dependent amplification of a target sequence present on a nucleic acid template is achieved in the con- tacting step.
- the degree of amplification has been found to increase with increasing numbers of primers. Examples are provided below using as many as 13 primers (seven sense and six complementary), and as few as two primers (two complementary primers). These examples illustrate the abil- ity of primers to cause amplification and are not intended to limit the invention.
- the complementary primer set and the sense primer set each contain more than two primers. In preferred embodiments, at least 4 sense primers and 4 complementary primers are used; at least 7 sense primers and 7 complementary primers are used; and at least 10 sense primers and 10 complementary primers are used.
- a set of complementary primers comprise oligonucleotides complementary to the template in regions 3′ of the target sequence.
- a set of sense primers comprise oligonucleotides analogous to the tem- plate in regions 5′ of the target sequence on the same strand.
- the oligonucleotides are selected so a primer extension reaction is initiated on the nucleic acid template at a site different from the other oligonucleotide primers, and pref- erably at a site distinct from the region in which the other oligonucleotide primers form base pairs.
- the oligonucleotides in a primer set are separated at their closest 5′ and 3′ ends from one another by 1 to 200 bases, and more preferably, are separated by between 1 and 10 bases.
- nucleotides By “four different nucleotides” is meant that adenosine (A), guanosine (G), cytidine (C) thymidine (T), and uridine (U) triphosphates, or an equivalent nucleotide which can be substituted for an adenosine, guanosine, cytidine, thymidine, or uridine nucleotide triphosphate, are present as substrates for nucleic acid synthesis. Preferably, deoxynucleotides are used.
- amplifying is meant increasing the number of target sequences.
- contacting is meant that the nucleic acid template, the nucleic acid polymerase, the four different nucleotides, and the oligonucleotide primer array are brought together under primer extension conditions.
- the temperature is kept below the temperature at which the template:primer extension product duplex dissociates.
- the tem- perature is kept below 90° C.
- the reaction temperature is maintained at about the optimum temperature for the reaction. Generally, such an optimum is between 42° C. and 60° C. and is preferably between 50° C. and 70° C.
- the conditions include the provision of DMSO; the essentially constant temperature is at least 43° C., and most preferably between 50° C. and 70° C.; the conditions include a strand separation agent such as a helicase, at least one nucleotide triphosphate, selected from a protein having an activity corresponding to the RecA protein of E. coli, or a single-stranded nucleic acid binding protein; the DNA polymerase is a 5′ exominus Bst DNA polymerase I or a modified Taq DNA polymerase; and at least one of the oligonucleotide primers includes a 5′ non-complementary region.
- the RecA protein is not necessary for amplification in this invention, but rather can be used to enhance such amplification.
- 5′ exonuclease minus is meant that the nucleic acid polymerase has essentially no 5′ exonuclease activity asso- ciated with it, or has been treated such that the exonuclease activity is reduced or inactive.
- the preferred nucleic acid polymerase is a 5′ exonuclease minus DNA polymerase.
- DNA polymerases having no 5′ exonuclease activity include a proteolytic fragment of DNA polymerase I from Bacillus stearothermophilus, and the DNA poly- merase from Thermus aquaticus having its domain encoding 5′ exonuclease activity removed as described by Barnes, “Thermostable DNA Polymerase,” PCT/US91/07084.
- the exonuclease minus polymerase of the Klenow fragment described by Walker, supra, may also be used.
- the invention features a method and means for amplifying a nucleic acid target sequence by the step of contacting the nucleic acid containing the target sequence with a nucleic acid polymerase that may have 5′ exonuclease activity but under conditions wherein such activity is inhibited.
- a nucleic acid polymerase that may have 5′ exonuclease activity but under conditions wherein such activity is inhibited.
- at least one oligonucleotide primer is modified to be resistant to nucleolytic degradation by any 5′-exonuclease present in the nucleic acid poly- merase.
- at least one complementary and one sense primer is modified to be resistant to 5′-exonuclease activity. More preferably all primers are resistant to such degradation.
- the contacting step contains four different nucleotide triphosphates, at least two different complementary oligonucleotide primers and at least two different oligonucleotide sense primers, one or more of which are blocked.
- the reaction is carried out under oligo- nucleotide primer extension conditions at essentially con- stant temperature in the absence of a restriction endonu- clease active on the products of any extension reaction of the contacting step.
- amplification is carried out using a primer array and either a 5′-exo-minus DNA polymerase or a DNA polymerase containing 5′ exonuclease activity used in conjunction with a 5′-exonuclease resistant primers.
- the present invention does not require a restriction endonuclease active on the products of any primer extension reaction resulting from the contacting step.
- a restriction endonuclease active on the products of any primer extension reaction resulting from the contacting step In contrast to the description in Walker, supra, where the presence of such activity appears to be essential, Applicant has surprisingly found that no restriction enzyme is needed to create a single-stranded region which can be used by oligonucleotide primers in the contacting step.
- the invention features a method for amplifying a target nucleic acid sequence by contacting a nucleic acid strand containing the target sequence with a nucleic acid polymerase lacking 5′ exonuclease activity, four different nucleotides, a set of at least two complementary oligonucleotide primers, and a set of at least two sense primers.
- the amplification is carried out under primer exten- sion conditions at essentially constant temperature in the absence of any restriction endonuclease active on the prod- ucts of any extension reaction.
- the amplification is prefer- ably carried out as described above.
- amplification is performed without any restriction endonuclease active on the products of any extension reaction using a nucleic acid polymerase containing 5′ exonuclease activity in conjunction with a 5′-exonuclease- resistant primer; or a single stranded DNA substrate and either a 5′-exo-minus DNA polymerase or a DNA poly- merase containing 5′ exonuclease activity used in conjunc- tion with a 5′-exonuclease-resistant primer.
- Such amplifica- tions are preferably carried out as described above.
- amplification can be allowed to proceed for any desired length of time with product accumulating as a result of amplification of the target sequence.
- high sensitivity detection of the target sequence can be accomplished by amplifying the target in the manner of the present invention and then detecting the accumulated amplification product using techniques known in the art.
- the present amplification method provides a number of significant benefits.
- the present method requires only a nucleic acid polymerase as opposed to several different enzymes, amplification of a specific nucleic acid sequence is more efficient and requires less reagent than a random amplification process, and there is no need for time-consuming and cumbersome thermal cycling.
- the FIGURE is an example illustrating the location of primers relative to each other and a target sequence.
- the FIGURE shows four complementary primers (“ ⁇ ”), four sense (“+”) primers, and the location of a target sequence (rectangular box).
- the present invention features methods for amplifying a target nucleic acid sequence present in a nucleic acid, or a mixture of nucleic acids, by a process which includes synthesis of nucleic acid sequences in a specifically-primed template-dependent manner with a nucleic acid polymerase (e.g., a DNA polymerase) and oligonucleotides primers, preferably, a primer array.
- a primer array is made up of a set of complementary primers and a set of sense primers. Nucleic acid synthesis is initiated at a complementary primer. Without being bound to any theory, it is believed that primer-dependent synthesis occurring from one primer causes strand displacement of a strand synthesized from a different primer.
- the amplification can be performed without modi- fying reaction conditions such as temperature, pH, or ionic strength during the amplification procedure to alternatively carry out amplification and denature the double-stranded nucleic acid produced during amplification.
- amplification can be performed without producing single-stranded substrates using enzymes having exonuclease activity or restriction endonuclease activity.
- the process includes the step of priming template nucleic acid strands with a primer array of sequence-specific oligo- nucleotide primers, for each different target sequence to be amplified.
- the mixture is incubated in the presence of a nucleic acid polymerase, nucleotide substrates, and any necessary co-factors needed to amplify the target nucleic acid sequence.
- primer refers to an oligonucleotide (whether occurring naturally as in a purified restriction digest, or produced synthetically) which can act as a point of initiation of nucleic acid synthesis on a nucleic acid template when contacted under primer extension conditions.
- Appropriate conditions include the presence of nucleotide substrates, a nucleic acid polymerase (e.g., a 5′-exo-minus DNA polymerase), essentially constant temperature and a suitable pH.
- the nucleic acid synthesis occurs in a template-dependent manner wherein the sequence of the newly syn- thesized nucleic acid strand is complementary to the sequence of the nucleic acid template.
- Hybridization of the primer to the template may be inhibited by primer secondary structure arising from intramolecular or intermolecular hydrogen bonding.
- the primer preferably lacks secondary structure and is single-stranded.
- a primer having a secondary structure which would inhibit hybridization to the template is prefer- ably treated to denature or separate its strand(s) prior to amplification.
- the primer is an oligodeoxynucleotide and is sufficiently long to be used as a substrate for the synthesis of extension products by a nucleic acid polymerase.
- the appro- priate primer length should take into account several factors, including temperature, structure of primer, and how the primer is used.
- the oligonucleotide primer typically contains at least 15 nucle- otides depending on the complexity of the target sequence. Other applications may require shorter oligonucleotide primers. It may be desirable to carry out these other appli- cation at cooler temperatures to form stable hybrid com- plexes with the template.
- a nucleic acid polymerase as used in the invention refers to a chemical, physical, or biological agent which brings about the synthesis of either ribo- or deoxyribonucleotides into a nucleic acid polymer, or strand, in a template-dependent manner.
- nucleic acid polymerases include DNA polymerases. DNA polymerases bring about nucleic acid synthesis in a template-dependent manner in a 5′ to 3′ direction. Because of the complementarity between the template and the synthesized strand, this direction would be from a 3′ region on the template to a 5′ region on the template.
- DNA polymerase I The large fragment of DNA polymerase I from Bacillus stearothermophilus (Bst DNA polymerase I) lack- ing 5′-3′ exonucleolytic activity is a preferred DNA poly- merase.
- Other suitable DNA polymerases include Klenow polymerase and bacteriophage T7 DNA polymerase.
- Klenow polymerase The use of 5′ blocked primers not susceptible to nucleolytic degra- dation should allow the use of DNA polymerases possessing 5′-3′ exonucleolytic activity.
- Complementary primers are selected to have a region complementary to the nucleic acid template.
- the primer sequence need not reflect the exact sequence of the template but must be able to hybridize with a template strand.
- Non-complementary bases can be interspersed into the primer provided the primer sequence has sufficient comple- mentarity to hybridize with its corresponding sequence in the nucleic acid template such that the extension reaction can occur.
- the newly-formed extension product once displaced, can act as a template for additional nucleic acid synthesis.
- the primers contain a non-complementary 5′ region.
- the preferred primer contains a complementary region enabling it to hybridize to the nucleic acid template, and a non-complementary region. The presence of a non-complementary region has been found to enhance strand displacement.
- the primer sequence can include one or more of the deoxyribonucleotide bases A, T, C, or G; and/or, one or more of the ribonucleotide bases A, U, C, or G and/or one or more modified nucleotide (deoxyribonucleotide or ribonucleotide) wherein the modification does not prevent hybridization of the primer to the nucleic acid, or elongation of the primer, or strand displacement.
- modified nucleotide deoxyribonucleotide or ribonucleotide
- Primers may be modified with chemical groups to enhance their performance or to facilitate the characteriza- tion of amplification products.
- backbone-modified oligonucleotides such as phosphorothioates or methylphosphonates which are resistant to the nucleolytic activity of certain polymerases allow the use of such enzymes.
- Another example of modification involves using non-nucleotide linkers (e.g., Arnold et al., EPA 88 308 766-0) which do not interfere with elongation of the primer.
- Oligonucleotides containing mixtures of the desired modi- fied and natural nucleotides may be used as well.
- Primers may also contain reactive sites for enzymes such as restriction endonuclease cleavage sites or promotor sites for RNA polymerases. Examples of the use of such sites include cloning of amplification products and transcription of amplification products after amplification. Such sites are not necessary for amplification, but are helpful for subse- quent manipulations of the amplified nucleic acids.
- the primers of the present invention can be prepared by methods known in the art.
- the primers are synthesized by chemical methods.
- Caruthers et al. in: Methods In Enzymology, vol. 154, p. 287 (1987), describe using standard phosphoramidite solid-phase chem- istry to join nucleotides by phosphodiester linkages.
- the phosphite linkage is then oxidized to a stable linkage and the process is cycled with the desired nucleotide residues introduced into the synthesized sequence.
- the oxidative procedure can result in a typical phosphate ester or a phosphorothioate ester (Arnold et al., supra, EPA 88 308 766-0).
- Introduction of non-nucleotide phosphoramidite derivatives can be performed during automated synthesis.
- the synthesized oligonucleotide can be further modi- fied by synthetic methods (e.g., as described in U.S. Pat. No. 4,818,681).
- the 5′ end of the primer can be modified to be resistant to 5′-exonuclease activity present in nucleic acid polymerase.
- modifications can be carried out by adding a non-nucleotide group to the terminal 5′ nucleotide of the primer using techniques such as those described by Arnold et al., U.S. Pat. No. 5,585,481, entitled “Linking Reagents for Nucleotide Probes,” and the CLONTECH product catalogue describing the use of label-ONTM regents, hereby incorpo- rated by reference herein.
- any source of nucleic acid in purified or non-purified form, can be utilized as the starting nucleic acid or acids provided it contains or is suspected of containing the target nucleic acid sequence.
- the starting nucleic acid may need to be purified prior to amplification. Purification of starting nucleic acid is preferably carried out when the nucleic acid source contains substances which inhibit amplification. Nucleic acid purification can be carried out using standard techniques.
- the target sequence may be present in DNA or RNA, which may be single-stranded or double-stranded. A mixture of these nucleic acids or the nucleic acid from a previous amplification may also be utilized.
- the nucleic acid or mixture of nucleic acids may contain more than one target nucleic acid sequence which may be the same or different. The invention is therefore useful for simultaneously ampli- fying one or more different target nucleic acid sequences located on the same or different target nucleic acid strands.
- the sample suspected or known to contain the intended target nucleic acid may be obtained from a variety of sources.
- sources include a biological sample; a food or agricultural sample; an environmental sample; body fluid or exudate such as urine, blood, milk, cerebrospinal fluid, sputum, saliva, stool, lung aspirates; and throat or genital swabs.
- test samples may be desirable to treat the test samples to obtain nucleic acids suitable for amplification.
- Such treatments can remove impurities which inhibit amplification, and denature the nucleic acid to minimize the secondary structure (i.e., double-stranded DNA and hairpin loops) .
- These treatments can be carried out by means well known in the art.
- Primers are designed to hybridize to specified regions of the target nucleic acid. Two sets of primers are preferably used. One set of primers, complementary primers, are designed to hybridize to a nucleic acid sequence present on the template nucleic acid 3′ to the target sequence. Hybrid- ization takes place based on hydrogen bonding between complementary nucleotides. The other set of primers, sense primers, are designed to be analogous to regions present on the template nucleic acid 5′ to the target sequence. The members of each primer set are co-linearly arranged as shown diagrammatically in the FIGURE.
- Both sets of primers are positioned such that the target sequence, present in the template and the complement to the template, will be amplified.
- DNA polymerases catalyze nucleic acid synthesis in a 5′ to 3′ direction (with respect to the template nucleotides are added from a 3′ template region to a 5′ template region).
- a complementary strand is produced from the initial template using the complementary primer. The complementary strand can act as a template for template-dependent nucleic acid synthesis.
- the sense primer is analogous to a region on the nucleic acid template 5′ to the target sequence, it will be comple- mentary to a region 3′ to the target sequence on the comple- mentary strand.
- the sense primer can act as a complemen- tary primer with respect to the complementary strand. Template-dependent nucleic acid synthesis can then occur on the complementary strand thereby producing more target sequence.
- the total number of complementary primers and sense primers is preferably more than 5.
- at least 4 sense primers and 4 complementary primers are used; at least 7 sense primers and 7 complementary primers are used; and at least 10 sense primers and 10 complemen- tary primers are used.
- the number of complementary prim- ers need not equal the number of sense primers. For example, a 2 sense primer and 3 complementary primer combination may be used.
- a heat-stable nucleic acid polymerase such as a thermostable DNA polymerase may be employed. The temperature selected depends on the temperature range within which the enzyme is active.
- nucleic acid polymerase and nucleotides must be used in sufficient quantity to support the degree of amplification desired.
- Nucleotide analogs can be substituted or added provided the base pairing, DNA polymerase, and strand-displacing functions are not adversely affected to the point that the amplification does not proceed to the desired extent.
- “Strand displacement” refers to the dissociation of a nucleic acid strand from its nucleic acid template in a 5′ to 3′ direction occurring due to template-directed nucleic acid synthesis by a nucleic acid polymerase.
- the newly synthe- sized and displaced nucleic acids have substantially the same nucleotide sequence which is complementary to the template nucleic acid sequence.
- a strand separation agent is used to enhance the strand displacement.
- Strand separation agents include enzymes such as helicases, the enzyme RecA which has helicase activity, and single-stranded nucleic acid binding protein.
- the use of helicases for separating strands of nucleic acid is described in Cold Spring Harbor Symposia on Quantitative Biology, Vol. XLIII, “DNA: Replication and Recombination” (New York: Cold Spring Harbor Laboratory, 1978) and the use of RecA is reviewed by Radding, Ann. Rev. Genetics, 16: 405 (1982). Strand sepa- ration is discussed by Kornberg, A, DNA Replication W. H. Freeman & Co., San Francisco, Calif., 1980. Zarling et al., U.S. Pat. No. 5,223,414 (Jun, 1993) discusses the use of RecA in nucleic acid hybridization and amplification.
- Amplification refers to increasing the number of target sequences.
- the degree of amplification can be increased by using conditions or agents which increase rates or extent of priming, or primer elongation.
- a stand separation agent may increase the strand displacement rate of a DNA polymerase.
- the nucleotide substrates or the primers can include a detectable label which is incorporated into newly synthesized DNA.
- the resulting labeled ampli- fication product is then separated from the unused labeled nucleotides or primers and the label is detected in the separated product fraction.
- Radioactive isotopes e.g., 32 p, 3 H, 1251, and 14 C
- fluorescent compounds e.g., 32 p, 3 H, 1251, and 14 C
- chemilu- minescent compounds e.g., chromophores
- ligands such as biotin and haptens which, while not directly detectable, can be readily detected by reaction with labeled forms of their specific binding partners, e.g., avidin and antibodies, respectively.
- Another approach is to detect the amplification product by hybridization with a detectable nucleic acid probe and measuring the resulting hybrids in any conventional manner.
- the product can be assayed by hybridizing a chemiluminescent acridinium ester-labeled nucleic acid probe to the target sequence, selectively hydrolyzing the acridinium ester present on unhybridized probe, and mea- suring the chemiluminescence produced from the remaining acridinium ester in a luminometer.
- a chemiluminescent acridinium ester-labeled nucleic acid probe to the target sequence, selectively hydrolyzing the acridinium ester present on unhybridized probe, and mea- suring the chemiluminescence produced from the remaining acridinium ester in a luminometer.
- This example illustrates the amplification of a ribosomal RNA(rRNA) target sequence by producing a DNA template, and amplifying the DNA template using a primer array and a 5′-exo-minus DNA polymerase.
- Production of the DNA template from rRNA, and amplification of the template, was carried out in the same reaction vessel containing the necessary reagents for production and amplification of the DNA template.
- the primer array used in this example comprised thirteen primers.
- the primers were prepared by standard phosphora- midite chemistry. Seven of the primers were complementary primers (with respect to the rRNA target). These primers had the following nucleic acid sequences (written 5′ to 3′):
- Target 23S rRNA was obtained from Chlamydia tra- chomatis (See, Glisin et al., Biochemistry 13:2633 (1974)), and diluted in buffer (50 mM Tris-HCl (PH 8.3), 37.5 mM KCl, 1.5 mM MgCl 2 , 10 mM DTT) . Variable amounts of rRNA target were combined with primers (7 ⁇ 10 ⁇ 12 mole) in 20 ⁇ l of buffer (7% DMSO, 50 mM Tris-HCl (pH 8.3) 75 mM KCl, 3 mM MgCl 2 , and 2 mM DTT) and incubated at 60° C.
- pre-hybridize the primers were then treated with 0.2 mM ATP, 0.2 mM TTP, 0.2 mM GTP, 0.2 mM CTP, 200 units of Maloney Murine Leukemia Virus reverse transcriptase (MMLV-RT), and 2 units of Bst DNA polymerase 1. Ampli- fication was carried out at 37° C. for 60 minutes, then at 60° C. for 120 minutes.
- the amplification products were then denatured and assayed using acridinium ester labeled probe according to Nelson et al., supra. Denaturation was carried out by incu- bating at 95° C. for 5 minutes. Probe labeling with acri- dinium ester was carried out as described by Nelson et al., supra. The acridinium ester labeled probe was synthesized to have the nucleic acid sequence corresponding to SEQ. ID. NO. 27. The acridinium ester labeled probe (2 ⁇ 10 ⁇ 11 moles) was incubated with amplified product at 60°60 C.
- hybridization buffer 100 mM lithium succinate (pH 5.2), 8% lithium dodecyl sulfate, 1.5 mM EDTA, and 1.5 mM EGTA.
- the acridinium ester present on unhybridized probe was then hydrolyzed by adding a reagent solution (0.15 M sodium tetraborate, pH 7.6, and 5% (v/v) Triton X-100) and incubating at 60° C. for 10 minutes. The remaining chemiluminescence was measured in a lumi- nometer.
- Table 1 demonstrate a titration of the target nucleic acid in the amplification method of the present invention.
- This example illustrates the amplification of an rRNA target sequence present in a clinical sample (cervical swab sample).
- the oligonucleotides, amplification procedure, and detection procedure used in this example were as described in Example 1. This example differs from Example 1 in the type of sample used, and sample preparation.
- Cervical swab samples were collected and suspended in a buffered solution containing an anionic detergent (60 mM phosphate buffer (pH 6.8), 6% lithium dodecyl sulfate, 2 mM EDTA, and 2 mM EGTA).
- the clinical specimen was spiked with 10-18 moles of 23S Chamydia trachomatis rRNA, hybridized with the primers, amplified, and detected, as described in Example 1.
- a successful amplification of target nucleic acid in the clinical sample was indicated by the clinical sample with Chlamydia rRNA having an RLU over 50 fold greater than a clinical sample without Chlamy- dia rRNA.
- This example illustrates the amplification of a specific target sequence using probes directed to a target sequence and a non-target sequence (i.e., a region of the transcript outside the amplicon).
- the target nucleic acid used in this example was derived from gene 10 of 17 bacteriophage.
- an XmaI and BanI digest of pGEMX1 containing part of gene 10 of T7 bacteriophage was sub-cloned into pUC19. Expression of the insert with T7 RNA polymerase yielded an RNA product 863 bases in length and this transcript was used to produce a DNA template which was then amplified.
- the primer array used to amplify the target sequence, was made up of four complementary primers (with respect to the RNA transcript) having the following nucleic acid sequences (written 5′ to 31′):
- Hybridization, amplification, and detection were carried out as described in Example 1.
- Acridinium ester-labeled probes SEQ. ID. NO: 22 and SEQ. ID. NO. 27 were used to detect the presence of the target sequence.
- a non-target acridinium ester labeled probe SEQ. ID. NO. 23 was used as a control to determine non-specific amplification occur- ring outside the primer region (e.g., 3′ of the complementary primers and 5′ the sense primers) .
- the results shown in Table 2 demonstrate that the amplification is specific.
- This example demonstrates the ability of a non-complementary region, attached to a primer, to enhance strand displacement and amplification.
- Strand displacement was measured using two different combinations of comple- mentary primers. Both combinations contained a 5′- 32 p labeled primer (SEQ. ID. NO. 19) and an additional primer.
- the additional primer in one combination corresponded to SEQ. ID. NO. 24.
- the additional primer in the other combination corresponded to SEQ. ID. NO. 25.
- the SEQ. ID. NO. 25 primer was similar to the SEQ. ID. NO. 24 primer, but had five fewer complementary nucleotides and contained a 5′ non-complementary region.
- Amplification was carried out on an oligodeoxynucleotide template corre- sponding to a portion of the T7 bacteriophage gene 10.
- the template corresponding to SEQ. ID. NO: 26, was synthe- sized as described in Example 1.
- the primers 4′10 ⁇ 32 mole were prehybridized with template (4 ⁇ 10 ⁇ 13 mole) in 20 ⁇ l of buffer (50 mM Tris-HCl (PH 8.3), 37.5 mM KCl, 1.5 MM MgCl 2 , 10 mM DTT), by incubating at 70° C. for 5 minutes, and the reaction was then allowed to cool to room temperature (about 20-25° C.) over the course of about 2 hours.
- Amplification was carried out by adding 0.1 mM ATP, 0.1 mM TTP, 0.1 mM GTP, 0.1 mM CTP, 4 units Bst DNA polymerase I and incubating at 50° C.
- the results shown in Table 3 demonstrate that strand displacement is more efficient using primers with a 5′ non-complementary region.
- the “% product” refers to the amount of elongation product divided by the sum of the amount of elongation product and primer. The higher per- centage of product observed with the primer having a 5′ non-complementary region indicates increased amplifica- tion and strand displacement.
- each reaction mixture contained a radiolabeled primer having the nucleotide sequence of SEQ. ID. NO. 19.
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Saccharide Compounds (AREA)
- Enzymes And Modification Thereof (AREA)
Abstract
Description
-
- The Qβ replicase (QβR) method described in PCT Pub- lication No. 87-06270 and U.S. Pat. No. 4,786,600 uses a specific RNA probe which is capable of specific transcrip- tion by a replicase enzyme. The method requires the design and synthesis of RNA probes with replicase initiation sites.
-
- The process includes the steps of priming single-stranded template nucleic acid strands with an excess of random oligonucleotide primers and incubating the single-stranded template nucleic acid strands and excess ran- dom oligonucleotide primers in the presence of excess amounts of an inducing agent, a strand displacement agent, and nucleoside triphosphate substrates to ran- domly amplify nucleic acid strands.
- SEQ. ID. NO. 1: CGCGTCTAGT CCTACTCAGG TGTTG
- SEQ. ID. NO. 2: CCCCAGATTC AGACTAGG
- SEQ. ID. NO. 3: CGGTCATTGA CTAGTATTTA GCCTT
- SEQ. ID. NO. 4: TTTCTTCATA GTACTGGTTC ACT
- SEQ. ID. NO. 5: ATTTCACTCC CTTAACAAGG GTT
- SEQ. ID. NO. 6: TTGTAAGCTA CAGGTTTCAG GT
- SEQ. ID. NO. 7: ACGGGCAATT GGTCTGCGAC C
Six of the primers were sense primers (with respect to the rRNA target). These primers had the following nucleic acid sequences (written 5′ to 3′): - SEQ. ID. NO. 8: AGCAAAGACC CGGAGGTCCG AAT
- SEQ. ID. NO. 9: GAATACATAG GTATGCAAAG CGA
- SEQ. ID. NO. 10: CCTGCCGAAC TGAAACATCT TAGT
- SEQ. ID. NO. 11: CAGAGGAAAA GAAATCGAAG AGAT
- SEQ. ID. NO. 12: TGTAGGATTG AGGATAAAGG AT
- SEQ. ID. NO. 13: GGACTCCTAG TTGAACACAT CTG- GAAAGA
TABLE 1 | |||
Chlamydia rRNA (Moles) | RLU (mean) | ||
4 × 10−18 | 307893 | ||
4 × 10−19 | 54771 | ||
4 × 10−20 | 3644 | ||
4 × 10−23 | 2354 | ||
0 | 2307 | ||
- SEQ. ID. NO. 14 CTATAGGGAG ACCACAACGG TTT
- SEQ. ID. NO. 15 CTAGAAATAA TTTTGTTTAA CTT
- SEQ. ID. NO. 16 AGAAGGAGAT ATACATATGG CT
- SEQ. ID. NO. 17 CATGACTGGT GGACAGCAAA TG
and four primers having the same sense as the RNA transcript, having the following nucleic acid sequences (written 5′ to 3′): - SEQ. ID. NO. 18 GAGCGAACGC AGTCAGGA
- SEQ. ID. NO. 19 GAGAAGTGGT CACGGAGGTA CGAGCGAACG CAGT
- SEQ. ID. NO. 20 GGAGATGGAA CGTACCATGT
- SEQ. ID. NO. 21 GGGAACTGAG CGGATTTACC GC
TABLE 2 | ||||
Probe | Sample | RLU (mean) | ||
SEQ. ID. 22 + | (4 × 10−19 mole) | 240474 | ||
SEQ. ID. 27 | ||||
SEQ. ID. 23 | (4 × 10−19 mole) | 3091 | ||
SEQ. ID. 23 | no target | 2720 | ||
TABLE 3 | ||||||
Primer (SEQ. | 24 | 24 | 24 | 25 | 25 | 25 |
ID. NO)1 | ||||||
Time | 5 min | 15 min | 30 min | 5 min | 15 min | 30 min |
% Product | 4.3 | 5.8 | 5.9 | 18 | 25 | 35 |
1In addition to the primers listed in Table 4, each reaction mixture contained a radiolabeled primer having the nucleotide sequence of SEQ. ID. NO. 19. |
Claims (42)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/164,833 USRE39007E1 (en) | 1994-03-16 | 2002-06-07 | Isothermal strand displacement nucleic acid amplification |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US21508194A | 1994-03-16 | 1994-03-16 | |
US08/972,799 US6087133A (en) | 1994-03-16 | 1997-11-18 | Isothermal strand displacement nucleic acid amplification |
US10/164,833 USRE39007E1 (en) | 1994-03-16 | 2002-06-07 | Isothermal strand displacement nucleic acid amplification |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US08/972,799 Reissue US6087133A (en) | 1994-03-16 | 1997-11-18 | Isothermal strand displacement nucleic acid amplification |
Publications (1)
Publication Number | Publication Date |
---|---|
USRE39007E1 true USRE39007E1 (en) | 2006-03-07 |
Family
ID=22801567
Family Applications (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US08/972,799 Ceased US6087133A (en) | 1994-03-16 | 1997-11-18 | Isothermal strand displacement nucleic acid amplification |
US09/506,282 Ceased US6214587B1 (en) | 1994-03-16 | 2000-02-17 | Isothermal strand displacement nucleic acid amplification |
US10/164,833 Expired - Lifetime USRE39007E1 (en) | 1994-03-16 | 2002-06-07 | Isothermal strand displacement nucleic acid amplification |
US10/165,281 Expired - Lifetime USRE38960E1 (en) | 1994-03-16 | 2002-06-07 | Isothermal strand displacement nucleic acid amplification |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US08/972,799 Ceased US6087133A (en) | 1994-03-16 | 1997-11-18 | Isothermal strand displacement nucleic acid amplification |
US09/506,282 Ceased US6214587B1 (en) | 1994-03-16 | 2000-02-17 | Isothermal strand displacement nucleic acid amplification |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/165,281 Expired - Lifetime USRE38960E1 (en) | 1994-03-16 | 2002-06-07 | Isothermal strand displacement nucleic acid amplification |
Country Status (11)
Country | Link |
---|---|
US (4) | US6087133A (en) |
EP (1) | EP0676476B1 (en) |
JP (1) | JPH09510351A (en) |
KR (1) | KR100230718B1 (en) |
AT (1) | ATE207543T1 (en) |
AU (1) | AU687535B2 (en) |
CA (1) | CA2185239C (en) |
DE (1) | DE69523360T2 (en) |
DK (1) | DK0676476T3 (en) |
ES (1) | ES2164112T3 (en) |
WO (1) | WO1995025180A1 (en) |
Cited By (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040126764A1 (en) * | 2002-12-20 | 2004-07-01 | Lasken Roger S. | Nucleic acid amplification |
US20040191784A1 (en) * | 2003-03-31 | 2004-09-30 | Patricio Abarzua | Universal reagents for rolling circle amplification and methods of use |
US20080057543A1 (en) * | 2006-05-05 | 2008-03-06 | Christian Korfhage | Insertion of Sequence Elements into Nucleic Acids |
US20080128298A1 (en) * | 2001-10-15 | 2008-06-05 | Carole Bornarth | Nucleic acid amplification |
US7501254B2 (en) | 2006-07-20 | 2009-03-10 | Ghc Technologies, Inc. | Methods and compositions for amplification and capture of nucleic acid sequences |
US20100015602A1 (en) * | 2005-04-01 | 2010-01-21 | Qiagen Gmbh | Reverse transcription and amplification of rna with simultaneous degradation of dna |
WO2011150277A2 (en) | 2010-05-28 | 2011-12-01 | Life Technologies Corporation | Synthesis of 2', 3'-dideoxynucleosides for automated dna synthesis and pyrophosphorolysis activated polymerization |
WO2012018964A1 (en) | 2010-08-03 | 2012-02-09 | Life Technologies Corporation | Detection of salmonella enterica subspecies enterica serovar enteritidis in food and environmental samples, methods and compositions thereof |
WO2012099896A2 (en) | 2011-01-17 | 2012-07-26 | Life Technologies Corporation | Workflow for detection of ligands using nucleic acids |
WO2012159025A2 (en) | 2011-05-18 | 2012-11-22 | Life Technologies Corporation | Chromosome conformation analysis |
WO2012170908A1 (en) | 2011-06-08 | 2012-12-13 | Life Technologies Corporation | Design and development of novel detergents for use in pcr systems |
WO2012170907A2 (en) | 2011-06-08 | 2012-12-13 | Life Technologies Corporation | Polymerization of nucleic acids using proteins having low isoelectric points |
WO2013188839A1 (en) | 2012-06-14 | 2013-12-19 | Life Technologies Corporation | Novel compositions, methods and kits for real time polymerase chain reaction (pcr) |
WO2014071315A1 (en) | 2012-11-02 | 2014-05-08 | Life Technologies Corporation | Novel compositions, methods and kits for enhancing pcr specificity |
WO2014070975A1 (en) | 2012-11-02 | 2014-05-08 | Novartis Ag | Flavivirus associated with theiler's disease |
WO2014165210A2 (en) | 2013-03-12 | 2014-10-09 | Life Technologies Corporation | Universal reporter-based genotyping methods and materials |
WO2015061714A1 (en) | 2013-10-25 | 2015-04-30 | Life Technologies Corporation | Novel compounds for use in pcr systems and applications thereof |
US9155992B2 (en) | 2013-09-16 | 2015-10-13 | Savannah River Nuclear Solutions, Llc | Mass transfer apparatus and method for separation of gases |
US9309565B2 (en) | 2010-05-14 | 2016-04-12 | Life Technologies Corporation | Karyotyping assay |
WO2016061111A1 (en) | 2014-10-13 | 2016-04-21 | Life Technologies Corporation | Methods, kits & compositions for determining gene copy numbers |
WO2016149021A1 (en) | 2015-03-13 | 2016-09-22 | Life Technologies Corporation | Methods, compositions and kits for small rna capture, detection and quantification |
US9683255B2 (en) | 2005-09-09 | 2017-06-20 | Qiagen Gmbh | Method for activating a nucleic acid for a polymerase reaction |
WO2017218938A1 (en) | 2016-06-16 | 2017-12-21 | Life Technologies Corporation | Novel compositions, methods and kits for microorganism detection |
EP3272885A2 (en) | 2011-01-14 | 2018-01-24 | Life Technologies Corporation | Methods for isolation, identification, and quantification of mirnas |
WO2018039599A1 (en) | 2016-08-26 | 2018-03-01 | Life Technologies Corporation | Nucleic acid extraction and amplification controls and methods of use thereof |
WO2019094973A1 (en) | 2017-11-13 | 2019-05-16 | Life Technologies Corporation | Compositions, methods and kits for urinary tract microorganism detection |
US10913981B2 (en) | 2013-11-12 | 2021-02-09 | Life Technologies Corporation | Reagents and methods for sequencing |
WO2022020731A2 (en) | 2020-07-23 | 2022-01-27 | Life Technologies Corporation | Compositions, systems and methods for biological analysis involving energy transfer dye conjugates and analytes comprising the same |
WO2022020723A1 (en) | 2020-07-23 | 2022-01-27 | Life Technologies Corporation | Energy transfer dye conjugates for use in biological assays |
US11572591B2 (en) | 2017-04-26 | 2023-02-07 | The Translational Genomics Research Institute | Methods and assays for subtyping Staphylococcus aureus clonal complex 8 strains |
Families Citing this family (271)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2185239C (en) * | 1994-03-16 | 2002-12-17 | Nanibhushan Dattagupta | Isothermal strand displacement nucleic acid amplification |
US5514551A (en) * | 1994-10-14 | 1996-05-07 | Gen-Probe Incorporated | Compositions for the detection of Chlamydia trachomatis |
AT402203B (en) * | 1995-06-13 | 1997-03-25 | Himmler Gottfried Dipl Ing Dr | METHOD FOR TRANSCRIPTION-FREE AMPLIFICATION OF NUCLEIC ACIDS |
WO1997011196A2 (en) * | 1995-09-21 | 1997-03-27 | Becton, Dickinson And Company | Detection of nucleic acids in cells by thermophilic strand displacement amplification |
ES2402947T3 (en) | 1997-04-10 | 2013-05-10 | Stichting Katholieke Universiteit University Medical Centre Nijmegen | PCA3, PCA3 genes and methods of use |
GB9717061D0 (en) * | 1997-08-13 | 1997-10-15 | Tepnel Medical Ltd | Amplification of nucleic acids |
US6124120A (en) * | 1997-10-08 | 2000-09-26 | Yale University | Multiple displacement amplification |
EP1098996A1 (en) | 1998-07-20 | 2001-05-16 | Yale University | Method for detecting nucleic acids using target-mediated ligation of bipartite primers |
EP1112385A1 (en) * | 1998-09-15 | 2001-07-04 | Yale University | Artificial long terminal repeat vectors |
JP2002525049A (en) | 1998-09-15 | 2002-08-13 | イェール ユニバーシティ | Molecular cloning using rolling circle amplification |
ATE321857T1 (en) * | 1999-09-29 | 2006-04-15 | Diagnocure Inc | PCA3 MRNA IN BENIGN AND MAGNIFICENT PROSTATE TISSUES |
AU2001244677A1 (en) * | 2000-04-07 | 2001-10-23 | Eiken Kagaku Kabushiki Kaisha | Method of amplifying nucleic acid by using double-stranded nucleic acid as template |
US20060166227A1 (en) * | 2000-06-20 | 2006-07-27 | Stephen Kingsmore | Protein expression profiling |
US6323009B1 (en) * | 2000-06-28 | 2001-11-27 | Molecular Staging, Inc. | Multiply-primed amplification of nucleic acid sequences |
CA2835978C (en) | 2000-09-01 | 2016-10-11 | Gen-Probe Incorporated | Amplification of hiv-1 sequences for detection of sequences associated with drug-resistance mutations |
KR20030064420A (en) * | 2000-12-26 | 2003-07-31 | 다카라 바이오 가부시키가이샤 | Method of detecting pathogenic microorganism |
JPWO2002062993A1 (en) * | 2001-02-06 | 2004-06-10 | タカラバイオ株式会社 | Amplified nucleic acid and immobilized product thereof |
CA2450217A1 (en) * | 2001-05-14 | 2002-11-21 | Henry Hongjun Ji | Novel method for cloning variable domain sequences of immunological gene repertoire |
US8137911B2 (en) | 2001-05-22 | 2012-03-20 | Cellscript, Inc. | Preparation and use of single-stranded transcription substrates for synthesis of transcription products corresponding to target sequences |
EA006679B1 (en) * | 2001-06-12 | 2006-02-24 | Такара Био Инк. | Method of stabilizing reagent for amplifying or detecting nucleic acid and storage method |
US7118864B2 (en) * | 2001-06-15 | 2006-10-10 | Quiatech Ab | Amplifiable probe |
CA2492220C (en) | 2001-07-15 | 2014-03-18 | Keck Graduate Institute | Nucleic acid amplification using nicking agents |
CA2492032A1 (en) * | 2001-07-15 | 2003-08-14 | Keck Graduate Institute | Gene expression analysis using nicking agents |
CA2492007A1 (en) | 2001-07-15 | 2003-01-30 | Keck Graduate Institute | Amplification of nucleic acid fragments using nicking agents |
EP1420069A4 (en) | 2001-08-20 | 2005-11-02 | Takara Bio Inc | Nucleic acid amplification methods |
US6617137B2 (en) | 2001-10-15 | 2003-09-09 | Molecular Staging Inc. | Method of amplifying whole genomes without subjecting the genome to denaturing conditions |
US6977148B2 (en) * | 2001-10-15 | 2005-12-20 | Qiagen Gmbh | Multiple displacement amplification |
US7553619B2 (en) * | 2002-02-08 | 2009-06-30 | Qiagen Gmbh | Detection method using dissociated rolling circle amplification |
EP1481088B1 (en) * | 2002-03-01 | 2008-09-17 | Integrated Dna Technologies, Inc. | Polynomial amplification of nucleic acids |
US7629152B2 (en) * | 2002-03-01 | 2009-12-08 | Integrated Dna Technologies, Inc. | Methods for amplifying polymeric nucleic acids |
US7405062B2 (en) * | 2002-05-14 | 2008-07-29 | San Diego Antibody | Method for cloning variable domain sequences of immunological gene repertoire |
US7282328B2 (en) * | 2002-09-20 | 2007-10-16 | New England Biolabs, Inc. | Helicase dependent amplification of nucleic acids |
US7662594B2 (en) | 2002-09-20 | 2010-02-16 | New England Biolabs, Inc. | Helicase-dependent amplification of RNA |
EP1585824A4 (en) | 2002-11-21 | 2008-01-02 | Epict Technologies | Preparation and use of single-stranded transcription substrates for synthesis of transcription products corresponding to target sequences |
JP4185763B2 (en) * | 2002-12-12 | 2008-11-26 | 富士フイルム株式会社 | Quantification method of target nucleic acid |
AU2003299694A1 (en) | 2002-12-20 | 2004-07-22 | Qiagen Gmbh | Nucleic acid amplification |
US7955795B2 (en) * | 2003-06-06 | 2011-06-07 | Qiagen Gmbh | Method of whole genome amplification with reduced artifact production |
AU2004209578A1 (en) * | 2003-02-07 | 2004-08-19 | Diagnocure Inc. | Method to detect prostate cancer in a sample |
AU2004276722B2 (en) | 2003-05-19 | 2009-03-12 | Gen-Probe Incorporated | Compositions, methods and kits for determining the presence of trichomonas vaginalis in a test sample |
US20040248103A1 (en) * | 2003-06-04 | 2004-12-09 | Feaver William John | Proximity-mediated rolling circle amplification |
US20050181394A1 (en) * | 2003-06-20 | 2005-08-18 | Illumina, Inc. | Methods and compositions for whole genome amplification and genotyping |
US20040259100A1 (en) | 2003-06-20 | 2004-12-23 | Illumina, Inc. | Methods and compositions for whole genome amplification and genotyping |
EP1636337A4 (en) | 2003-06-20 | 2007-07-04 | Illumina Inc | Methods and compositions for whole genome amplification and genotyping |
US20050069926A1 (en) * | 2003-08-01 | 2005-03-31 | Affymetrix, Inc. | Helicase-amplified reverse transcription |
EP1715037B1 (en) | 2003-12-10 | 2010-02-17 | Takara Bio Inc. | Method of amplifying nucleic acid |
US7314714B2 (en) | 2003-12-19 | 2008-01-01 | Affymetrix, Inc. | Method of oligonucleotide synthesis |
EP2415878A1 (en) | 2003-12-25 | 2012-02-08 | Riken | Method of amplifying nucleic acid and method of detecting mutated nucleic acid using the same |
JP4929153B2 (en) | 2004-03-05 | 2012-05-09 | ジェン−プロウブ インコーポレイテッド | Reagents, methods, and kits for use in inactivating nucleic acids |
EP2383350B1 (en) | 2004-05-07 | 2018-07-11 | Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. | Methods of diagnosing or treating prostate cancer using the erg gene, alone or in combination with other over or under expressed genes in prostate cancer |
KR101506727B1 (en) | 2004-05-13 | 2015-04-03 | 나노바이오심 인크. | Nano-PCR: Methods and devices for nucleic acid amplification and detection |
GB0416944D0 (en) * | 2004-07-29 | 2004-09-01 | Lumora Ltd | Method for determining the amount of template nucleic acid present in a sample |
US20060216724A1 (en) * | 2004-07-30 | 2006-09-28 | Affymetrix, Inc. | Methods for normalized amplification of nucleic acids |
US20060275792A1 (en) * | 2004-11-15 | 2006-12-07 | Lee Jun E | Enhancement of nucleic acid amplification using double-stranded DNA binding proteins |
CA2491067A1 (en) | 2004-12-24 | 2006-06-24 | Stichting Katholieke Universiteit | Mrna rations in urinary sediments and/or urine as a prognostic marker for prostate cancer |
WO2006122401A1 (en) * | 2005-05-16 | 2006-11-23 | Institut De Recherches Cliniques De Montreal/I.R.C.M. | Negative regulation of nk cell functions by eat-2, a sap-related adaptor expressed in innate immune cells |
EP1929045B9 (en) * | 2005-09-06 | 2012-06-20 | Gen-Probe Incorporated | Methods, compositions and kits for isothermal amplification of nucleic acids |
ATE537251T1 (en) | 2005-10-06 | 2011-12-15 | Lucigen Corp | TEMPERATURE STABLE VIRAL POLYMERASES AND METHODS OF USE |
KR100816419B1 (en) * | 2005-10-14 | 2008-03-27 | 래플진(주) | Method for Isothermal Amplification of Nucleic Acids and Method for Detecting Nucleic Acids Using Simultaneous Isothermal Amplification of Nucleic Acids and Signal Probe |
US20080057499A1 (en) * | 2006-02-06 | 2008-03-06 | Affymetrix, Inc. | Methods for high specificity whole genome amplification and hybridization |
JP2009534033A (en) | 2006-04-21 | 2009-09-24 | ナノバイオシン,インコーポレイテッド | Single molecule platform for drug discovery: methods and devices for drug discovery including discovery of anticancer and antiviral agents |
AU2007244658B2 (en) | 2006-04-28 | 2014-02-13 | Igor Kutyavin | Use of base-modified deoxynucleoside triphosphates |
WO2007127999A2 (en) * | 2006-04-28 | 2007-11-08 | Igor Kutyavin | Use of products of pcr amplification carrying elements of secondary structure to improve pcr-based nucleic acid detection |
US8980561B1 (en) | 2006-08-22 | 2015-03-17 | Los Alamos National Security, Llc. | Nucleic acid detection system and method for detecting influenza |
WO2008105814A2 (en) | 2006-08-22 | 2008-09-04 | Los Alamos National Security, Llc | Miniturized lateral flow device for rapid and sensitive detection of proteins or nucleic acids |
US20080182312A1 (en) * | 2007-01-17 | 2008-07-31 | Todd Denison Pack | Stable reagents and kits useful in loop-mediated isothermal amplification (LAMP) |
CA2622649C (en) | 2007-03-09 | 2018-04-24 | Riken | Nucleic acid amplification method using primer exhibiting exciton effect |
WO2008116186A1 (en) | 2007-03-22 | 2008-09-25 | Keck Graduate Institute | Systems and devices for isothermal biochemical reactions and/or analysis |
ES2725003T3 (en) * | 2007-03-28 | 2019-09-18 | Signal Diagnostics | High resolution nucleic acid analysis system and method to detect sequence variations |
US9689031B2 (en) | 2007-07-14 | 2017-06-27 | Ionian Technologies, Inc. | Nicking and extension amplification reaction for the exponential amplification of nucleic acids |
EP2232259B1 (en) | 2008-01-09 | 2016-10-12 | Keck Graduate Institute | System, apparatus and method for material preparation and/or handling |
US20090215050A1 (en) * | 2008-02-22 | 2009-08-27 | Robert Delmar Jenison | Systems and methods for point-of-care amplification and detection of polynucleotides |
WO2009137059A1 (en) | 2008-05-05 | 2009-11-12 | Los Alamos National Security, Llc | Highly simplified lateral flow-based nucleic acid sample preparation and passive fluid flow control |
US8383345B2 (en) | 2008-09-12 | 2013-02-26 | University Of Washington | Sequence tag directed subassembly of short sequencing reads into long sequencing reads |
PT2963709T (en) | 2008-10-24 | 2017-08-21 | Epicentre Tech Corp | Transposon end compositions and methods for modifying nucleic acids |
US9080211B2 (en) | 2008-10-24 | 2015-07-14 | Epicentre Technologies Corporation | Transposon end compositions and methods for modifying nucleic acids |
US10669574B2 (en) | 2008-11-18 | 2020-06-02 | XCR Diagnostics, Inc. | DNA amplification technology |
US20100285473A1 (en) | 2009-01-27 | 2010-11-11 | John Wolff | Thermophilic helicase dependent amplification technology with endpoint homogenous fluorescent detection |
US8685648B2 (en) | 2009-02-03 | 2014-04-01 | Biohelix Corporation | Endonuclease-enhanced helicase-dependent amplification |
DK3255146T3 (en) | 2009-03-16 | 2019-08-19 | Pangu Biopharma Ltd | Compositions and Methods comprising Histidyl-tRNA Synthetase Splicing Variants with Non-Canonical Biological Activities |
US20100310576A1 (en) | 2009-03-31 | 2010-12-09 | Adams Ryan A | COMPOSITIONS AND METHODS COMPRISING ASPARTYL-tRNA SYNTHETASES HAVING NON-CANONICAL BIOLOGICAL ACTIVITIES |
EP2446047B1 (en) | 2009-06-26 | 2017-10-18 | Claremont Biosolutions LLC | Capture and elution of bio-analytes via beads that are used to disrupt specimens |
CA2787327C (en) | 2010-01-22 | 2015-09-15 | Damon Kittredge Getman | Probes for detecting the presence of trichomonas vaginalis in a sample |
US20190300945A1 (en) | 2010-04-05 | 2019-10-03 | Prognosys Biosciences, Inc. | Spatially Encoded Biological Assays |
PL2556171T3 (en) | 2010-04-05 | 2016-04-29 | Prognosys Biosciences Inc | Spatially encoded biological assays |
US10787701B2 (en) | 2010-04-05 | 2020-09-29 | Prognosys Biosciences, Inc. | Spatially encoded biological assays |
US8980253B2 (en) | 2010-04-26 | 2015-03-17 | Atyr Pharma, Inc. | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of cysteinyl-tRNA synthetase |
CN103096911B (en) | 2010-04-27 | 2018-05-29 | Atyr 医药公司 | Treatment relevant with the protein fragments of Isoleucyl-tRNA synthetase, diagnosis and the innovation of antibody compositions are found |
AU2011248489B2 (en) | 2010-04-28 | 2016-10-06 | Pangu Biopharma Limited | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of alanyl tRNA synthetases |
EP2563383B1 (en) | 2010-04-29 | 2017-03-01 | Atyr Pharma, Inc. | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of valyl trna synthetases |
WO2011150279A2 (en) | 2010-05-27 | 2011-12-01 | Atyr Pharma, Inc. | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of glutaminyl-trna synthetases |
CN103097523B (en) | 2010-04-29 | 2016-09-28 | Atyr医药公司 | The innovation for the treatment of, diagnosis and the antibody compositions relevant to the protein fragments of Asparaginyl-tRNA synthetase finds |
CA2800557A1 (en) | 2010-04-29 | 2011-11-03 | Medical Prognosis Institute A/S | Methods and devices for predicting treatment efficacy |
EP2566496B1 (en) | 2010-05-03 | 2018-02-28 | aTyr Pharma, Inc. | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of methionyl-trna synthetases |
US9034321B2 (en) | 2010-05-03 | 2015-05-19 | Atyr Pharma, Inc. | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of phenylalanyl-alpha-tRNA synthetases |
CA2797277C (en) | 2010-05-03 | 2021-02-23 | Atyr Pharma, Inc. | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of arginyl-trna synthetases |
CA2798139C (en) | 2010-05-04 | 2019-09-24 | Atyr Pharma, Inc. | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of p38 multi-trna synthetase complex |
CN103200953B (en) | 2010-05-14 | 2017-02-15 | Atyr 医药公司 | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of phenylalanyl-beta-trna synthetases |
CN103096914B (en) | 2010-05-17 | 2015-08-12 | Atyr医药公司 | The innovation of the treatment relevant to the protein fragments of Leucyl-tRNA synthetase, diagnosis and antibody compositions finds |
AU2011261486B2 (en) | 2010-06-01 | 2017-02-23 | Pangu Biopharma Limited | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of lysyl-tRNA synthetases |
EP2593125B1 (en) | 2010-07-12 | 2017-11-01 | aTyr Pharma, Inc. | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of glycyl-trna synthetases |
EP2420579A1 (en) | 2010-08-17 | 2012-02-22 | QIAGEN GmbH | Helicase dependent isothermal amplification using nicking enzymes |
CN103108650A (en) | 2010-08-25 | 2013-05-15 | Atyr医药公司 | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of tyrosyl-trna synthetases |
US20120100549A1 (en) * | 2010-10-01 | 2012-04-26 | Ibis Biosciences, Inc. | Targeted genome amplification methods |
US9074251B2 (en) | 2011-02-10 | 2015-07-07 | Illumina, Inc. | Linking sequence reads using paired code tags |
US10457936B2 (en) | 2011-02-02 | 2019-10-29 | University Of Washington Through Its Center For Commercialization | Massively parallel contiguity mapping |
GB201106254D0 (en) | 2011-04-13 | 2011-05-25 | Frisen Jonas | Method and product |
DK2699700T3 (en) | 2011-04-20 | 2016-08-01 | Mesa Biotech Inc | Integrated device for nukleinsyreregistrering and identification |
EP2714927B1 (en) | 2011-06-01 | 2016-08-10 | Medical Prognosis Institute A/S | Methods and devices for prognosis of cancer relapse |
WO2013035875A1 (en) | 2011-09-08 | 2013-03-14 | 独立行政法人理化学研究所 | Primer set, method for amplifying target nucleic acid sequence using same, and method for detecting mutated nucleic acid using same |
US9352312B2 (en) | 2011-09-23 | 2016-05-31 | Alere Switzerland Gmbh | System and apparatus for reactions |
US9528107B2 (en) * | 2012-01-31 | 2016-12-27 | Pacific Biosciences Of California, Inc. | Compositions and methods for selection of nucleic acids |
KR20140123571A (en) | 2012-02-16 | 2014-10-22 | 에이티와이알 파마, 인코포레이티드 | Histidyl-trna synthetases for treating autoimmune and inflammatory diseases |
US9012022B2 (en) | 2012-06-08 | 2015-04-21 | Illumina, Inc. | Polymer coatings |
US8895249B2 (en) | 2012-06-15 | 2014-11-25 | Illumina, Inc. | Kinetic exclusion amplification of nucleic acid libraries |
US10870099B2 (en) | 2012-07-26 | 2020-12-22 | Illumina, Inc. | Compositions and methods for the amplification of nucleic acids |
US9181583B2 (en) | 2012-10-23 | 2015-11-10 | Illumina, Inc. | HLA typing using selective amplification and sequencing |
WO2014085434A1 (en) | 2012-11-27 | 2014-06-05 | Pontificia Universidad Catolica De Chile | Compositions and methods for diagnosing thyroid tumors |
CN105531375B (en) | 2012-12-10 | 2020-03-03 | 分析生物科学有限公司 | Method for targeted genomic analysis |
US9074248B1 (en) | 2012-12-18 | 2015-07-07 | Qiagen Gmbh | Primers for helicase dependent amplification and their methods of use |
US9683230B2 (en) | 2013-01-09 | 2017-06-20 | Illumina Cambridge Limited | Sample preparation on a solid support |
US9512422B2 (en) | 2013-02-26 | 2016-12-06 | Illumina, Inc. | Gel patterned surfaces |
CA2898453C (en) | 2013-03-13 | 2021-07-27 | Illumina, Inc. | Multilayer fluidic devices and methods for their fabrication |
WO2014142850A1 (en) | 2013-03-13 | 2014-09-18 | Illumina, Inc. | Methods and compositions for nucleic acid sequencing |
WO2014140167A1 (en) | 2013-03-14 | 2014-09-18 | Dsm Ip Assets B.V. | Cell wall deconstruction enzymes of malbranchea cinnamomea and uses thereof |
WO2014140165A1 (en) | 2013-03-14 | 2014-09-18 | Dsm Ip Assets B.V. | Cell wall deconstruction enzymes of paecilomyces byssochlamydoides and uses thereof |
US10933417B2 (en) | 2013-03-15 | 2021-03-02 | Nanobiosym, Inc. | Systems and methods for mobile device analysis of nucleic acids and proteins |
WO2014195032A1 (en) | 2013-06-07 | 2014-12-11 | Medical Prognosis Institute A/S | Methods and devices for predicting treatment efficacy of fulvestrant in cancer patients |
US9868979B2 (en) | 2013-06-25 | 2018-01-16 | Prognosys Biosciences, Inc. | Spatially encoded biological assays using a microfluidic device |
ES2899618T3 (en) | 2013-07-01 | 2022-03-14 | Illumina Inc | Catalyst-free surface functionalization and polymer grafting |
SG10201806890VA (en) | 2013-08-28 | 2018-09-27 | Cellular Res Inc | Massively parallel single cell analysis |
KR102323375B1 (en) | 2013-10-09 | 2021-11-08 | 플루어레센트릭 인코포레이티드 | Multiplex Probes |
EP3080268A1 (en) | 2013-12-09 | 2016-10-19 | Illumina, Inc. | Methods and compositions for targeted nucleic acid sequencing |
EP3957750A1 (en) | 2013-12-20 | 2022-02-23 | Illumina, Inc. | Preserving genomic connectivity information in fragmented genomic dna samples |
WO2015108663A1 (en) | 2014-01-16 | 2015-07-23 | Illumina, Inc. | Amplicon preparation and sequencing on solid supports |
US9677132B2 (en) | 2014-01-16 | 2017-06-13 | Illumina, Inc. | Polynucleotide modification on solid support |
AU2015239394B2 (en) | 2014-03-31 | 2017-11-02 | Kabushiki Kaisha Dnaform | Fluorescent labeled single-stranded nucleic acid and use thereof |
US20150353989A1 (en) | 2014-06-09 | 2015-12-10 | Illumina Cambridge Limited | Sample preparation for nucleic acid amplification |
GB201410420D0 (en) | 2014-06-11 | 2014-07-23 | Illumina Cambridge Ltd | Methods for estimating cluster numbers |
US10017759B2 (en) | 2014-06-26 | 2018-07-10 | Illumina, Inc. | Library preparation of tagged nucleic acid |
CA2953791A1 (en) | 2014-06-30 | 2016-01-07 | Illumina, Inc. | Methods and compositions using one-sided transposition |
EP3169815B1 (en) | 2014-07-15 | 2020-12-23 | Ontario Institute For Cancer Research | Methods and devices for predicting anthracycline treatment efficacy |
CN106574302A (en) | 2014-08-04 | 2017-04-19 | 基因细胞生物系统有限公司 | Genomic analysis device and methods of use |
US9982250B2 (en) | 2014-08-21 | 2018-05-29 | Illumina Cambridge Limited | Reversible surface functionalization |
WO2016040602A1 (en) | 2014-09-11 | 2016-03-17 | Epicentre Technologies Corporation | Reduced representation bisulfite sequencing using uracil n-glycosylase (ung) and endonuclease iv |
IL299976A (en) | 2014-10-17 | 2023-03-01 | Illumina Cambridge Ltd | Contiguity preserving transposition |
PL3212684T3 (en) | 2014-10-31 | 2020-10-19 | Illumina Cambridge Limited | Polymers and dna copolymer coatings |
GB201419731D0 (en) | 2014-11-05 | 2014-12-17 | Illumina Cambridge Ltd | Sequencing from multiple primers to increase data rate and density |
AU2015346514B2 (en) | 2014-11-11 | 2021-04-08 | Illumina, Inc. | Polynucleotide amplification using CRISPR-Cas systems |
SG10202012249YA (en) | 2014-12-08 | 2021-01-28 | Berg Llc | Use of markers including filamin a in the diagnosis and treatment of prostate cancer |
EP3783109B1 (en) | 2015-03-31 | 2024-05-29 | Illumina Cambridge Limited | Surface concatamerization of templates |
ES2955916T3 (en) | 2015-04-10 | 2023-12-11 | Spatial Transcriptomics Ab | Multiplex analysis of biological specimens of spatially distinguished nucleic acids |
DK3760737T3 (en) | 2015-05-11 | 2023-04-11 | Illumina Inc | Platform for discovery and analysis of therapeutic agents |
ES2877205T3 (en) | 2015-07-06 | 2021-11-16 | Illumina Cambridge Ltd | Sample preparation for nucleic acid amplification |
CN107924121B (en) | 2015-07-07 | 2021-06-08 | 亿明达股份有限公司 | Selective surface patterning via nanoimprinting |
US20180207920A1 (en) | 2015-07-17 | 2018-07-26 | Illumina, Inc. | Polymer sheets for sequencing applications |
WO2017037078A1 (en) | 2015-09-02 | 2017-03-09 | Illumina Cambridge Limited | Systems and methods of improving droplet operations in fluidic systems |
SG11201805665UA (en) | 2016-03-28 | 2018-10-30 | Illumina Inc | Multi-plane microarrays |
US11542544B2 (en) | 2016-05-11 | 2023-01-03 | Illumina, Inc. | Polynucleotide enrichment and amplification using CRISPR-Cas or Argonaute systems |
KR102171865B1 (en) | 2016-05-18 | 2020-10-29 | 일루미나, 인코포레이티드 | Self-assembled patterning using patterned hydrophobic surfaces |
WO2017205957A1 (en) | 2016-06-01 | 2017-12-07 | 9087-4405 Quebec Inc. | Remote access system and method for plant pathogen management |
AU2017299803B2 (en) | 2016-07-22 | 2023-06-29 | Illumina, Inc. | Single cell whole genome libraries and combinatorial indexing methods of making thereof |
GB201704754D0 (en) | 2017-01-05 | 2017-05-10 | Illumina Inc | Kinetic exclusion amplification of nucleic acid libraries |
JP7229923B2 (en) | 2017-01-06 | 2023-02-28 | エディタス・メディシン、インコーポレイテッド | Methods for assessing nuclease cleavage |
EP3607087A4 (en) | 2017-04-04 | 2020-12-30 | Omniome, Inc. | Fluidic apparatus and methods useful for chemical and biological reactions |
ES2937929T3 (en) | 2017-04-23 | 2023-04-03 | Illumina Inc | Compositions and methods to improve sample identification in indexed nucleic acid libraries |
EP3615671B1 (en) | 2017-04-23 | 2021-07-21 | Illumina Cambridge Limited | Compositions and methods for improving sample identification in indexed nucleic acid libraries |
AU2018260627A1 (en) | 2017-04-23 | 2019-11-14 | Illumina Cambridge Limited | Compositions and methods for improving sample identification in indexed nucleic acid libraries |
US10914729B2 (en) | 2017-05-22 | 2021-02-09 | The Trustees Of Princeton University | Methods for detecting protein binding sequences and tagging nucleic acids |
EP4293122A3 (en) | 2017-06-07 | 2024-01-24 | Oregon Health & Science University | Single cell whole genome libraries for methylation sequencing |
CN110785813A (en) | 2017-07-31 | 2020-02-11 | 伊鲁米那股份有限公司 | Sequencing system with multi-path biological sample aggregation |
AU2018312560B2 (en) | 2017-08-01 | 2022-03-10 | Illumina, Inc. | Hydrogel beads for nucleotide sequencing |
EP3662083A4 (en) | 2017-08-01 | 2021-03-03 | Illumina, Inc. | Spatial indexing of genetic material and library preparation using hydrogel beads and flow cells |
JP2021500531A (en) | 2017-08-15 | 2021-01-07 | オムニオム インコーポレイテッドOmniome, Inc. | Scanning equipment and methods useful for detecting chemical and biological specimens |
EP3697932A1 (en) | 2017-10-19 | 2020-08-26 | Omniome, Inc. | Simultaneous background reduction and complex stabilization in binding assay workflows |
US10689629B1 (en) | 2017-12-06 | 2020-06-23 | Cepheid | Inhibition of nucleic acid polymerases by endonuclease V-cleavable circular oligonucleotide ligands |
US10724083B1 (en) | 2017-12-06 | 2020-07-28 | Cepheid | Inhibition of nucleic acid polymerases by endonuclease V-cleavable oligonucleotide ligands |
US10724017B1 (en) | 2017-12-06 | 2020-07-28 | Cepheid | Inhibition of DNA polymerases by uracil-DNA glycosylase-cleavable oligonucleotide ligands |
CA3186025A1 (en) | 2018-02-13 | 2019-08-22 | Illumina, Inc. | Dna sequencing using hydrogel beads |
KR20200024167A (en) | 2018-03-22 | 2020-03-06 | 일루미나, 인코포레이티드 | Preparation of Nucleic Acid Libraries from RNA and DNA |
US20190367909A1 (en) | 2018-04-02 | 2019-12-05 | Illumina, Inc. | Compositions and methods for making controls for sequence-based genetic testing |
US20190338352A1 (en) | 2018-04-19 | 2019-11-07 | Omniome, Inc. | Accuracy of base calls in nucleic acid sequencing methods |
MX2019014802A (en) | 2018-04-20 | 2021-03-02 | Illumina Inc | Methods of encapsulating single cells, the encapsulated cells and uses thereof. |
RU2744175C1 (en) | 2018-05-17 | 2021-03-03 | Иллумина, Инк. | High-performance single cell sequencing with reduced amplification error |
ES2966028T3 (en) | 2018-06-04 | 2024-04-18 | Illumina Inc | High-throughput single-cell transcriptome libraries and methods of preparation and use |
US20210310059A1 (en) | 2018-08-08 | 2021-10-07 | Gen-Probe Incorporated | Compositions, methods and kits for detecting mycoplasma genitalium |
US11519033B2 (en) | 2018-08-28 | 2022-12-06 | 10X Genomics, Inc. | Method for transposase-mediated spatial tagging and analyzing genomic DNA in a biological sample |
SG11202102703VA (en) | 2018-10-26 | 2021-04-29 | Illumina Inc | Modulating polymer beads for dna processing |
US20240011086A1 (en) | 2018-11-15 | 2024-01-11 | Omniome, Inc. | Electronic detection of nucleic acid structure |
BR112021006183A2 (en) | 2018-11-30 | 2021-06-29 | Illumina, Inc. | analysis of multiple analytes using a single assay |
CN211311477U (en) | 2018-12-04 | 2020-08-21 | 欧姆尼欧美公司 | Sequencing system |
EP3894592A2 (en) | 2018-12-10 | 2021-10-20 | 10X Genomics, Inc. | Generating spatial arrays with gradients |
AU2019402925A1 (en) | 2018-12-19 | 2021-01-14 | Illumina, Inc. | Methods for improving polynucleotide cluster clonality priority |
WO2020132350A2 (en) | 2018-12-20 | 2020-06-25 | Omniome, Inc. | Temperature control for analysis of nucleic acids and other analytes |
US11649485B2 (en) | 2019-01-06 | 2023-05-16 | 10X Genomics, Inc. | Generating capture probes for spatial analysis |
US11926867B2 (en) | 2019-01-06 | 2024-03-12 | 10X Genomics, Inc. | Generating capture probes for spatial analysis |
CN113613787B (en) | 2019-02-20 | 2023-06-13 | 加利福尼亚太平洋生物科学股份有限公司 | Scanning device and method for detecting chemical and biological analytes |
CA3113841A1 (en) | 2019-03-01 | 2020-09-10 | Illumina, Inc. | High-throughput single-nuclei and single-cell libraries and methods of making and of using |
EP3963099A1 (en) | 2019-04-30 | 2022-03-09 | Larimar Therapeutics, Inc. | Frataxin-sensitive markers for determining effectiveness of frataxin replacement therapy |
EP3976820A1 (en) | 2019-05-30 | 2022-04-06 | 10X Genomics, Inc. | Methods of detecting spatial heterogeneity of a biological sample |
US11644406B2 (en) | 2019-06-11 | 2023-05-09 | Pacific Biosciences Of California, Inc. | Calibrated focus sensing |
CN113226519A (en) | 2019-07-12 | 2021-08-06 | Illumina剑桥有限公司 | Preparation of nucleic acid libraries using electrophoresis |
CN113260711A (en) | 2019-07-12 | 2021-08-13 | Illumina剑桥有限公司 | Compositions and methods for preparing nucleic acid sequencing libraries using CRISPR/CAS9 immobilized on a solid support |
US10656368B1 (en) | 2019-07-24 | 2020-05-19 | Omniome, Inc. | Method and system for biological imaging using a wide field objective lens |
WO2021041056A1 (en) | 2019-08-23 | 2021-03-04 | Gen-Probe Incorporated | Compositions, methods and kits for detecting treponema pallidum |
CA3153514A1 (en) | 2019-09-05 | 2021-03-11 | Gen-Probe Incorporated | Detection of chlamydia trachomatis nucleic acid variants |
CN114728996B (en) | 2019-09-10 | 2022-11-29 | 加利福尼亚太平洋生物科学股份有限公司 | Reversible modification of nucleotides |
WO2021091611A1 (en) | 2019-11-08 | 2021-05-14 | 10X Genomics, Inc. | Spatially-tagged analyte capture agents for analyte multiplexing |
EP4025711A2 (en) | 2019-11-08 | 2022-07-13 | 10X Genomics, Inc. | Enhancing specificity of analyte binding |
CN114008199A (en) | 2019-12-19 | 2022-02-01 | 伊路敏纳公司 | High throughput single cell libraries and methods of making and using the same |
EP3891300B1 (en) | 2019-12-23 | 2023-03-29 | 10X Genomics, Inc. | Methods for spatial analysis using rna-templated ligation |
US11702693B2 (en) | 2020-01-21 | 2023-07-18 | 10X Genomics, Inc. | Methods for printing cells and generating arrays of barcoded cells |
US11732299B2 (en) | 2020-01-21 | 2023-08-22 | 10X Genomics, Inc. | Spatial assays with perturbed cells |
US11821035B1 (en) | 2020-01-29 | 2023-11-21 | 10X Genomics, Inc. | Compositions and methods of making gene expression libraries |
US11898205B2 (en) | 2020-02-03 | 2024-02-13 | 10X Genomics, Inc. | Increasing capture efficiency of spatial assays |
WO2021158511A1 (en) | 2020-02-04 | 2021-08-12 | Omniome, Inc. | Flow cells and methods for their manufacture and use |
US11732300B2 (en) | 2020-02-05 | 2023-08-22 | 10X Genomics, Inc. | Increasing efficiency of spatial analysis in a biological sample |
US11835462B2 (en) | 2020-02-11 | 2023-12-05 | 10X Genomics, Inc. | Methods and compositions for partitioning a biological sample |
US11891654B2 (en) | 2020-02-24 | 2024-02-06 | 10X Genomics, Inc. | Methods of making gene expression libraries |
US11926863B1 (en) | 2020-02-27 | 2024-03-12 | 10X Genomics, Inc. | Solid state single cell method for analyzing fixed biological cells |
US11768175B1 (en) | 2020-03-04 | 2023-09-26 | 10X Genomics, Inc. | Electrophoretic methods for spatial analysis |
BR112022019541A2 (en) | 2020-03-30 | 2022-11-16 | Illumina Inc | METHODS AND COMPOSITIONS FOR PREPARING NUCLEIC ACID LIBRARIES |
ES2965354T3 (en) | 2020-04-22 | 2024-04-12 | 10X Genomics Inc | Methods for spatial analysis using targeted RNA deletion |
WO2021231477A2 (en) | 2020-05-12 | 2021-11-18 | Illumina, Inc. | Generating nucleic acids with modified bases using recombinant terminal deoxynucleotidyl transferase |
AU2021275906A1 (en) | 2020-05-22 | 2022-12-22 | 10X Genomics, Inc. | Spatial analysis to detect sequence variants |
WO2021236929A1 (en) | 2020-05-22 | 2021-11-25 | 10X Genomics, Inc. | Simultaneous spatio-temporal measurement of gene expression and cellular activity |
WO2021242834A1 (en) | 2020-05-26 | 2021-12-02 | 10X Genomics, Inc. | Method for resetting an array |
EP4158054A1 (en) | 2020-06-02 | 2023-04-05 | 10X Genomics, Inc. | Spatial transcriptomics for antigen-receptors |
WO2021247543A2 (en) | 2020-06-02 | 2021-12-09 | 10X Genomics, Inc. | Nucleic acid library methods |
EP4162074B1 (en) | 2020-06-08 | 2024-04-24 | 10X Genomics, Inc. | Methods of determining a surgical margin and methods of use thereof |
WO2021252617A1 (en) | 2020-06-09 | 2021-12-16 | Illumina, Inc. | Methods for increasing yield of sequencing libraries |
EP4165207A1 (en) | 2020-06-10 | 2023-04-19 | 10X Genomics, Inc. | Methods for determining a location of an analyte in a biological sample |
CN116034166A (en) | 2020-06-25 | 2023-04-28 | 10X基因组学有限公司 | Spatial analysis of DNA methylation |
JP2023532231A (en) | 2020-06-30 | 2023-07-27 | イルミナ インコーポレイテッド | Sequencing by Catalytically Controlled Synthesis to Generate Unblemished DNA |
US11981960B1 (en) | 2020-07-06 | 2024-05-14 | 10X Genomics, Inc. | Spatial analysis utilizing degradable hydrogels |
US11761038B1 (en) | 2020-07-06 | 2023-09-19 | 10X Genomics, Inc. | Methods for identifying a location of an RNA in a biological sample |
EP4192951A1 (en) | 2020-08-06 | 2023-06-14 | Illumina, Inc. | Preparation of rna and dna sequencing libraries using bead-linked transposomes |
KR20230051508A (en) | 2020-08-18 | 2023-04-18 | 일루미나, 인코포레이티드 | Sequence-specific targeted translocation and selection and sorting of nucleic acids |
US11981958B1 (en) | 2020-08-20 | 2024-05-14 | 10X Genomics, Inc. | Methods for spatial analysis using DNA capture |
WO2022047359A1 (en) | 2020-08-31 | 2022-03-03 | Berg Llc | Protein biomarkers for pancreatic cancer |
MX2023001400A (en) | 2020-09-11 | 2023-04-25 | Illumina Cambridge Ltd | Methods of enriching a target sequence from a sequencing library using hairpin adaptors. |
US11926822B1 (en) | 2020-09-23 | 2024-03-12 | 10X Genomics, Inc. | Three-dimensional spatial analysis |
US11827935B1 (en) | 2020-11-19 | 2023-11-28 | 10X Genomics, Inc. | Methods for spatial analysis using rolling circle amplification and detection probes |
AU2021409136A1 (en) | 2020-12-21 | 2023-06-29 | 10X Genomics, Inc. | Methods, compositions, and systems for capturing probes and/or barcodes |
CA3208854A1 (en) | 2021-02-04 | 2022-08-11 | Illumina, Inc. | Long indexed-linked read generation on transposome bound beads |
MX2023010649A (en) | 2021-03-09 | 2023-09-20 | Illumina Inc | Analyzing expression of protein-coding variants in cells. |
EP4305163A1 (en) | 2021-03-09 | 2024-01-17 | Illumina, Inc. | Genomic library preparation and targeted epigenetic assays using cas-grna ribonucleoproteins |
EP4301870A1 (en) | 2021-03-18 | 2024-01-10 | 10X Genomics, Inc. | Multiplex capture of gene and protein expression from a biological sample |
AU2022245985A1 (en) | 2021-03-22 | 2023-09-21 | Illumina Cambridge Limited | Methods for improving nucleic acid cluster clonality |
JP2024513187A (en) | 2021-03-29 | 2024-03-22 | イルミナ インコーポレイテッド | Compositions and methods for assessing DNA damage and normalizing amplicon size bias in libraries |
BR112023019898A2 (en) | 2021-03-29 | 2023-11-07 | Illumina Inc | IMPROVED LIBRARY PREPARATION METHODS |
EP4314282A1 (en) | 2021-03-30 | 2024-02-07 | Illumina, Inc. | Improved methods of isothermal complementary dna and library preparation |
BR112023019945A2 (en) | 2021-03-31 | 2023-11-14 | Illumina Cambridge Ltd | METHODS FOR PREPARING SEQUENCING LIBRARIES BY DIRECTIONAL TAGGING USING TRANSPOSON-BASED TECHNOLOGY WITH UNIQUE MOLECULAR IDENTIFIERS FOR ERROR CORRECTION |
CA3214833A1 (en) | 2021-04-06 | 2022-10-13 | Bpgbio, Inc. | Protein markers for the prognosis of breast cancer progression |
EP4320441A1 (en) | 2021-04-06 | 2024-02-14 | BPGbio, Inc. | Protein markers for estrogen receptor (er)-positive-like and estrogen receptor (er)-negative-like breast cancer |
EP4320440A1 (en) | 2021-04-06 | 2024-02-14 | BPGbio, Inc. | Protein markers for estrogen receptor (er)-positive luminal a(la)-like and luminal b1 (lb1)-like breast cancer |
EP4337797A1 (en) | 2021-05-14 | 2024-03-20 | Gen-Probe Incorporated | Compositions and methods for detecting human adenovirus nucleic acid |
US20230016633A1 (en) | 2021-06-15 | 2023-01-19 | Illumina, Inc. | Hydrogel-free surface functionalization for sequencing |
US11427855B1 (en) | 2021-06-17 | 2022-08-30 | Element Biosciences, Inc. | Compositions and methods for pairwise sequencing |
US11859241B2 (en) | 2021-06-17 | 2024-01-02 | Element Biosciences, Inc. | Compositions and methods for pairwise sequencing |
CN117813391A (en) | 2021-07-23 | 2024-04-02 | 因美纳有限公司 | Method for preparing substrate surface for DNA sequencing |
CA3223731A1 (en) | 2021-08-11 | 2023-02-16 | Illumina, Inc. | Detection of analytes using targeted epigenetic assays, proximity-induced tagmentation, strand invasion, restriction, or ligation |
WO2023034489A1 (en) | 2021-09-01 | 2023-03-09 | 10X Genomics, Inc. | Methods, compositions, and kits for blocking a capture probe on a spatial array |
AU2022371198A1 (en) | 2021-10-20 | 2024-05-02 | Illumina, Inc. | Methods for capturing library dna for sequencing |
AU2023208743A1 (en) | 2022-01-20 | 2024-01-04 | Illumina, Inc. | Methods of detecting methylcytosine and hydroxymethylcytosine by sequencing |
WO2023196937A1 (en) | 2022-04-06 | 2023-10-12 | Larimar Therapeutics, Inc. | Frataxin-sensitive markers for monitoring frataxin replacement therapy |
AU2023248405A1 (en) | 2022-04-07 | 2024-01-04 | Illumina, Inc. | Altered cytidine deaminases and methods of use |
WO2023240201A1 (en) | 2022-06-08 | 2023-12-14 | Larimar Therapeutics, Inc. | Frataxin-sensitive markers for monitoring progression and treatment of leigh syndrome |
WO2024073047A1 (en) | 2022-09-30 | 2024-04-04 | Illumina, Inc. | Cytidine deaminases and methods of use in mapping modified cytosine nucleotides |
WO2024073043A1 (en) | 2022-09-30 | 2024-04-04 | Illumina, Inc. | Methods of using cpg binding proteins in mapping modified cytosine nucleotides |
WO2024069581A1 (en) | 2022-09-30 | 2024-04-04 | Illumina Singapore Pte. Ltd. | Helicase-cytidine deaminase complexes and methods of use |
WO2024129969A1 (en) | 2022-12-14 | 2024-06-20 | Illumina, Inc. | Systems and methods for capture and enrichment of clustered beads on flow cell substrates |
Citations (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0200362A2 (en) * | 1985-03-28 | 1986-11-05 | F. Hoffmann-La Roche Ag | Process for amplifying, detecting, and/or cloning nucleic acid sequences |
US4683195A (en) * | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
US4683202A (en) * | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
WO1987006270A1 (en) | 1986-04-16 | 1987-10-22 | The Salk Institute For Biological Studies | Replicative rna reporter systems |
US4786600A (en) * | 1984-05-25 | 1988-11-22 | The Trustees Of Columbia University In The City Of New York | Autocatalytic replication of recombinant RNA |
WO1988010315A1 (en) | 1987-06-19 | 1988-12-29 | Siska Diagnostics, Inc. | Transcription-based nucleic acid amplification/detection systems |
US4800159A (en) * | 1986-02-07 | 1989-01-24 | Cetus Corporation | Process for amplifying, detecting, and/or cloning nucleic acid sequences |
EP0300796A2 (en) * | 1987-07-23 | 1989-01-25 | Syntex (U.S.A.) Inc. | Amplification method for polynucleotide assays |
WO1989001050A1 (en) | 1987-07-31 | 1989-02-09 | The Board Of Trustees Of The Leland Stanford Junior University | Selective amplification of target polynucleotide sequences |
EP0320308A2 (en) * | 1987-12-11 | 1989-06-14 | Abbott Laboratories | Method for detecting a target nucleic acid sequence |
EP0329822A2 (en) * | 1988-02-24 | 1989-08-30 | Cangene Corporation | Nucleic acid amplification process |
EP0395398A2 (en) * | 1989-04-27 | 1990-10-31 | Life Technologies Inc. | Amplification of nucleic acid sequences using random sequence oligonucleotides as primers |
EP0408295A2 (en) * | 1989-07-11 | 1991-01-16 | Gen-Probe Incorporated | Nucleic acid sequence amplification methods |
WO1991002818A1 (en) | 1989-08-23 | 1991-03-07 | Cangene Corporation | Enhanced nucleic acid amplification process |
EP0427074A2 (en) | 1989-11-09 | 1991-05-15 | Miles Inc. | Nucleic acid amplification employing transcribable hairpin probe |
EP0427073A2 (en) | 1989-11-09 | 1991-05-15 | Miles Inc. | Nucleic acid amplification employing ligatable hairpin probe and transcription |
WO1991010746A1 (en) | 1990-01-10 | 1991-07-25 | Chiron Corporation | Dna-dependent rna polymerase transcripts as reporter molecules for signal amplification in nucleic acid hybridization assays |
US5108892A (en) * | 1989-08-03 | 1992-04-28 | Promega Corporation | Method of using a taq dna polymerase without 5'-3'-exonuclease activity |
EP0497272A1 (en) | 1991-01-31 | 1992-08-05 | Becton, Dickinson and Company | Strand displacement amplification |
EP0500224A2 (en) | 1991-01-31 | 1992-08-26 | Becton, Dickinson and Company | Exonuclease mediated strand displacement amplification |
EP0543612A2 (en) | 1991-11-19 | 1993-05-26 | Becton, Dickinson and Company | Nucleic acid target generation |
US5223414A (en) * | 1990-05-07 | 1993-06-29 | Sri International | Process for nucleic acid hybridization and amplification |
US5256775A (en) * | 1989-06-05 | 1993-10-26 | Gilead Sciences, Inc. | Exonuclease-resistant oligonucleotides |
WO1994003635A1 (en) | 1992-08-04 | 1994-02-17 | Institute Of Molecular Biology & Biotechnology | Rapid amplification and detection of nucleic acids |
US5384242A (en) * | 1989-04-17 | 1995-01-24 | Eastman Kodak Company | Diagnostic kit, primer composition and their use for replication or detection of nucleic acids |
US5786183A (en) | 1993-07-23 | 1998-07-28 | Gen-Probe Incorporated | Methods of enhancing nucleic acid amplification |
US6214587B1 (en) * | 1994-03-16 | 2001-04-10 | Gen-Probe Incorporated | Isothermal strand displacement nucleic acid amplification |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0476071A4 (en) * | 1989-06-05 | 1992-11-04 | Gilead Sciences, Inc. | Exonuclease-resistant oligonucleotides and methods for preparing the same |
-
1995
- 1995-03-14 CA CA002185239A patent/CA2185239C/en not_active Expired - Fee Related
- 1995-03-14 AU AU21016/95A patent/AU687535B2/en not_active Ceased
- 1995-03-14 WO PCT/US1995/003339 patent/WO1995025180A1/en active Application Filing
- 1995-03-14 KR KR1019960705103A patent/KR100230718B1/en not_active IP Right Cessation
- 1995-03-14 JP JP7524197A patent/JPH09510351A/en active Pending
- 1995-03-16 AT AT95103868T patent/ATE207543T1/en not_active IP Right Cessation
- 1995-03-16 DK DK95103868T patent/DK0676476T3/en active
- 1995-03-16 ES ES95103868T patent/ES2164112T3/en not_active Expired - Lifetime
- 1995-03-16 EP EP95103868A patent/EP0676476B1/en not_active Expired - Lifetime
- 1995-03-16 DE DE69523360T patent/DE69523360T2/en not_active Expired - Lifetime
-
1997
- 1997-11-18 US US08/972,799 patent/US6087133A/en not_active Ceased
-
2000
- 2000-02-17 US US09/506,282 patent/US6214587B1/en not_active Ceased
-
2002
- 2002-06-07 US US10/164,833 patent/USRE39007E1/en not_active Expired - Lifetime
- 2002-06-07 US US10/165,281 patent/USRE38960E1/en not_active Expired - Lifetime
Patent Citations (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4786600A (en) * | 1984-05-25 | 1988-11-22 | The Trustees Of Columbia University In The City Of New York | Autocatalytic replication of recombinant RNA |
EP0200362A2 (en) * | 1985-03-28 | 1986-11-05 | F. Hoffmann-La Roche Ag | Process for amplifying, detecting, and/or cloning nucleic acid sequences |
US4683202A (en) * | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
US4683202B1 (en) * | 1985-03-28 | 1990-11-27 | Cetus Corp | |
US4683195B1 (en) * | 1986-01-30 | 1990-11-27 | Cetus Corp | |
US4683195A (en) * | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
US4800159A (en) * | 1986-02-07 | 1989-01-24 | Cetus Corporation | Process for amplifying, detecting, and/or cloning nucleic acid sequences |
WO1987006270A1 (en) | 1986-04-16 | 1987-10-22 | The Salk Institute For Biological Studies | Replicative rna reporter systems |
WO1988010315A1 (en) | 1987-06-19 | 1988-12-29 | Siska Diagnostics, Inc. | Transcription-based nucleic acid amplification/detection systems |
EP0300796A2 (en) * | 1987-07-23 | 1989-01-25 | Syntex (U.S.A.) Inc. | Amplification method for polynucleotide assays |
WO1989001050A1 (en) | 1987-07-31 | 1989-02-09 | The Board Of Trustees Of The Leland Stanford Junior University | Selective amplification of target polynucleotide sequences |
EP0320308A2 (en) * | 1987-12-11 | 1989-06-14 | Abbott Laboratories | Method for detecting a target nucleic acid sequence |
EP0329822A2 (en) * | 1988-02-24 | 1989-08-30 | Cangene Corporation | Nucleic acid amplification process |
US5384242A (en) * | 1989-04-17 | 1995-01-24 | Eastman Kodak Company | Diagnostic kit, primer composition and their use for replication or detection of nucleic acids |
EP0395398A2 (en) * | 1989-04-27 | 1990-10-31 | Life Technologies Inc. | Amplification of nucleic acid sequences using random sequence oligonucleotides as primers |
US5043272A (en) * | 1989-04-27 | 1991-08-27 | Life Technologies, Incorporated | Amplification of nucleic acid sequences using oligonucleotides of random sequence as primers |
US5256775A (en) * | 1989-06-05 | 1993-10-26 | Gilead Sciences, Inc. | Exonuclease-resistant oligonucleotides |
EP0408295A2 (en) * | 1989-07-11 | 1991-01-16 | Gen-Probe Incorporated | Nucleic acid sequence amplification methods |
US5108892A (en) * | 1989-08-03 | 1992-04-28 | Promega Corporation | Method of using a taq dna polymerase without 5'-3'-exonuclease activity |
WO1991002818A1 (en) | 1989-08-23 | 1991-03-07 | Cangene Corporation | Enhanced nucleic acid amplification process |
EP0427073A2 (en) | 1989-11-09 | 1991-05-15 | Miles Inc. | Nucleic acid amplification employing ligatable hairpin probe and transcription |
EP0427074A2 (en) | 1989-11-09 | 1991-05-15 | Miles Inc. | Nucleic acid amplification employing transcribable hairpin probe |
WO1991010746A1 (en) | 1990-01-10 | 1991-07-25 | Chiron Corporation | Dna-dependent rna polymerase transcripts as reporter molecules for signal amplification in nucleic acid hybridization assays |
US5223414A (en) * | 1990-05-07 | 1993-06-29 | Sri International | Process for nucleic acid hybridization and amplification |
EP0497272A1 (en) | 1991-01-31 | 1992-08-05 | Becton, Dickinson and Company | Strand displacement amplification |
EP0500224A2 (en) | 1991-01-31 | 1992-08-26 | Becton, Dickinson and Company | Exonuclease mediated strand displacement amplification |
EP0543612A2 (en) | 1991-11-19 | 1993-05-26 | Becton, Dickinson and Company | Nucleic acid target generation |
US5270184A (en) * | 1991-11-19 | 1993-12-14 | Becton, Dickinson And Company | Nucleic acid target generation |
WO1994003635A1 (en) | 1992-08-04 | 1994-02-17 | Institute Of Molecular Biology & Biotechnology | Rapid amplification and detection of nucleic acids |
US5786183A (en) | 1993-07-23 | 1998-07-28 | Gen-Probe Incorporated | Methods of enhancing nucleic acid amplification |
US6214587B1 (en) * | 1994-03-16 | 2001-04-10 | Gen-Probe Incorporated | Isothermal strand displacement nucleic acid amplification |
Non-Patent Citations (8)
Cited By (51)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20080128298A1 (en) * | 2001-10-15 | 2008-06-05 | Carole Bornarth | Nucleic acid amplification |
US9487823B2 (en) | 2002-12-20 | 2016-11-08 | Qiagen Gmbh | Nucleic acid amplification |
US20040126764A1 (en) * | 2002-12-20 | 2004-07-01 | Lasken Roger S. | Nucleic acid amplification |
US20040191784A1 (en) * | 2003-03-31 | 2004-09-30 | Patricio Abarzua | Universal reagents for rolling circle amplification and methods of use |
US8043834B2 (en) | 2003-03-31 | 2011-10-25 | Qiagen Gmbh | Universal reagents for rolling circle amplification and methods of use |
US8309303B2 (en) | 2005-04-01 | 2012-11-13 | Qiagen Gmbh | Reverse transcription and amplification of RNA with simultaneous degradation of DNA |
US20100015602A1 (en) * | 2005-04-01 | 2010-01-21 | Qiagen Gmbh | Reverse transcription and amplification of rna with simultaneous degradation of dna |
US9683255B2 (en) | 2005-09-09 | 2017-06-20 | Qiagen Gmbh | Method for activating a nucleic acid for a polymerase reaction |
US20080057543A1 (en) * | 2006-05-05 | 2008-03-06 | Christian Korfhage | Insertion of Sequence Elements into Nucleic Acids |
US7501254B2 (en) | 2006-07-20 | 2009-03-10 | Ghc Technologies, Inc. | Methods and compositions for amplification and capture of nucleic acid sequences |
US11193165B2 (en) | 2010-05-14 | 2021-12-07 | Life Technologies Corporation | Karyotyping assay |
US9309565B2 (en) | 2010-05-14 | 2016-04-12 | Life Technologies Corporation | Karyotyping assay |
US9228227B2 (en) | 2010-05-28 | 2016-01-05 | Life Technologies Corporation | Synthesis of 2′, 3′-dideoxynucleosides for automated DNA synthesis and pyrophosphorolysis activated polymerization |
US9732112B2 (en) | 2010-05-28 | 2017-08-15 | Life Technologies Corporation | Synthesis of 2′,3′-dideoxynucleosides for automated DNA synthesis and pyrophosphorolysis activated polymerization |
WO2011150277A2 (en) | 2010-05-28 | 2011-12-01 | Life Technologies Corporation | Synthesis of 2', 3'-dideoxynucleosides for automated dna synthesis and pyrophosphorolysis activated polymerization |
US8658776B2 (en) | 2010-05-28 | 2014-02-25 | Life Technologies Corporation | Synthesis of 2′,3′-dideoxynucleosides for automated DNA synthesis and pyrophosphorolysis activated polymerization |
WO2012018964A1 (en) | 2010-08-03 | 2012-02-09 | Life Technologies Corporation | Detection of salmonella enterica subspecies enterica serovar enteritidis in food and environmental samples, methods and compositions thereof |
EP3733870A2 (en) | 2011-01-14 | 2020-11-04 | Life Technologies Corporation | Methods for identification and quantification of mirnas |
EP3272885A2 (en) | 2011-01-14 | 2018-01-24 | Life Technologies Corporation | Methods for isolation, identification, and quantification of mirnas |
WO2012099896A2 (en) | 2011-01-17 | 2012-07-26 | Life Technologies Corporation | Workflow for detection of ligands using nucleic acids |
EP3216878A1 (en) | 2011-01-17 | 2017-09-13 | Life Technologies Corporation | Workflow for detection of ligands using nucleic acids |
EP3567121A1 (en) | 2011-01-17 | 2019-11-13 | Life Technologies Corporation | Workflow for detection of ligands using nucleic acids |
WO2012159025A2 (en) | 2011-05-18 | 2012-11-22 | Life Technologies Corporation | Chromosome conformation analysis |
EP3461807A1 (en) | 2011-06-08 | 2019-04-03 | Life Technologies Corporation | Design and development of novel detergents for use in pcr systems |
EP4249603A2 (en) | 2011-06-08 | 2023-09-27 | Life Technologies Corporation | Design and development of novel detergents for use in pcr systems |
WO2012170908A1 (en) | 2011-06-08 | 2012-12-13 | Life Technologies Corporation | Design and development of novel detergents for use in pcr systems |
WO2012170907A2 (en) | 2011-06-08 | 2012-12-13 | Life Technologies Corporation | Polymerization of nucleic acids using proteins having low isoelectric points |
EP3643793A1 (en) | 2012-06-14 | 2020-04-29 | Life Technologies Corporation | Novel compositions, methods and kits for polymerase chain reaction (pcr) |
WO2013188839A1 (en) | 2012-06-14 | 2013-12-19 | Life Technologies Corporation | Novel compositions, methods and kits for real time polymerase chain reaction (pcr) |
WO2014070975A1 (en) | 2012-11-02 | 2014-05-08 | Novartis Ag | Flavivirus associated with theiler's disease |
WO2014071315A1 (en) | 2012-11-02 | 2014-05-08 | Life Technologies Corporation | Novel compositions, methods and kits for enhancing pcr specificity |
EP3260558A1 (en) | 2012-11-02 | 2017-12-27 | Life Technologies Corporation | Novel compositions and methods for enhancing pcr specificity |
EP3748016A1 (en) | 2012-11-02 | 2020-12-09 | Life Technologies Corporation | Novel compositions and methods for enhancing pcr specificity |
WO2014071322A1 (en) | 2012-11-02 | 2014-05-08 | Life Technologies Corporation | Small RNA Capture, Detection and Quantification |
EP3628746A1 (en) | 2012-11-02 | 2020-04-01 | Life Technologies Corporation | Small rna capture, detection and quantification |
WO2014165210A2 (en) | 2013-03-12 | 2014-10-09 | Life Technologies Corporation | Universal reporter-based genotyping methods and materials |
EP3640347A2 (en) | 2013-03-12 | 2020-04-22 | Life Technologies Corporation | Universal reporter-based genotyping methods and materials |
US9868084B2 (en) | 2013-09-16 | 2018-01-16 | Savannah River Nuclear Solutions, Llc | Mass transfer apparatus and method for separation of gases |
US9155992B2 (en) | 2013-09-16 | 2015-10-13 | Savannah River Nuclear Solutions, Llc | Mass transfer apparatus and method for separation of gases |
EP3539944A1 (en) | 2013-10-25 | 2019-09-18 | Life Technologies Corporation | Novel compounds for use in pcr systems and applications thereof |
WO2015061714A1 (en) | 2013-10-25 | 2015-04-30 | Life Technologies Corporation | Novel compounds for use in pcr systems and applications thereof |
US10913981B2 (en) | 2013-11-12 | 2021-02-09 | Life Technologies Corporation | Reagents and methods for sequencing |
WO2016061111A1 (en) | 2014-10-13 | 2016-04-21 | Life Technologies Corporation | Methods, kits & compositions for determining gene copy numbers |
WO2016149021A1 (en) | 2015-03-13 | 2016-09-22 | Life Technologies Corporation | Methods, compositions and kits for small rna capture, detection and quantification |
EP3967768A1 (en) | 2015-03-13 | 2022-03-16 | Life Technologies Corporation | Compositions for small rna capture, detection and quantification |
WO2017218938A1 (en) | 2016-06-16 | 2017-12-21 | Life Technologies Corporation | Novel compositions, methods and kits for microorganism detection |
WO2018039599A1 (en) | 2016-08-26 | 2018-03-01 | Life Technologies Corporation | Nucleic acid extraction and amplification controls and methods of use thereof |
US11572591B2 (en) | 2017-04-26 | 2023-02-07 | The Translational Genomics Research Institute | Methods and assays for subtyping Staphylococcus aureus clonal complex 8 strains |
WO2019094973A1 (en) | 2017-11-13 | 2019-05-16 | Life Technologies Corporation | Compositions, methods and kits for urinary tract microorganism detection |
WO2022020731A2 (en) | 2020-07-23 | 2022-01-27 | Life Technologies Corporation | Compositions, systems and methods for biological analysis involving energy transfer dye conjugates and analytes comprising the same |
WO2022020723A1 (en) | 2020-07-23 | 2022-01-27 | Life Technologies Corporation | Energy transfer dye conjugates for use in biological assays |
Also Published As
Publication number | Publication date |
---|---|
CA2185239C (en) | 2002-12-17 |
CA2185239A1 (en) | 1995-09-21 |
KR970701791A (en) | 1997-04-12 |
EP0676476A1 (en) | 1995-10-11 |
AU687535B2 (en) | 1998-02-26 |
USRE38960E1 (en) | 2006-01-31 |
WO1995025180A1 (en) | 1995-09-21 |
DK0676476T3 (en) | 2001-12-03 |
AU2101695A (en) | 1995-10-03 |
ES2164112T3 (en) | 2002-02-16 |
ATE207543T1 (en) | 2001-11-15 |
KR100230718B1 (en) | 1999-11-15 |
EP0676476B1 (en) | 2001-10-24 |
DE69523360D1 (en) | 2001-11-29 |
US6214587B1 (en) | 2001-04-10 |
DE69523360T2 (en) | 2002-07-11 |
US6087133A (en) | 2000-07-11 |
JPH09510351A (en) | 1997-10-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
USRE39007E1 (en) | Isothermal strand displacement nucleic acid amplification | |
JP7050848B2 (en) | Methods for Multiplexing Recombinase Polymerase Amplification | |
US5824517A (en) | Method for amplifying nucleic acid sequences by strand displacement using DNA/RNA chimeric primers | |
AU624601B2 (en) | Amplification and detection of nucleic acid sequences | |
JP3165431B2 (en) | Amplification method | |
JP3360977B2 (en) | Highly sensitive nucleic acid detection method | |
JP2807202B2 (en) | Highly sensitive nucleic acid detection method | |
EP0682120A1 (en) | Selective amplification of target polynucleotide sequences | |
AU2017328613A1 (en) | Methods for performing multiplexed PCR | |
JPH022934A (en) | Assay using template-depending nucleic acid probe reconstruction | |
KR20010012175A (en) | Two-step hybridization and capture of a polynucleotide | |
CN106574304B (en) | DNA amplification method based on strand invasion | |
US8153772B2 (en) | Oligonucleotide probes and primers comprising universal bases for diagnostic purposes | |
AU724804B2 (en) | Assay involving looped nucleic acid | |
US5925518A (en) | Nucleic acid primers for amplification of a mycobacteria RNA template | |
EP1017855B1 (en) | Methods of synthesizing polynucleotides by ligation of multiple oligomers | |
US20070122827A1 (en) | Target nucleic acid signal detection | |
US6001610A (en) | Method for the particularly sensitive detection of nucleic acids | |
JPH06327500A (en) | Method for multiplying nucleic acid sequence and method for detecting same | |
US6017739A (en) | Method and nucleic acid-concentratiing assay kit for concentrating mutant nucleic acid | |
CN115349019A (en) | Compositions, kits and methods for isolating target polynucleotides | |
JPH0731475A (en) | Method for amplifying and detecting target nucleic acid sequence using thermostable enzyme |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FPAY | Fee payment |
Year of fee payment: 8 |
|
FPAY | Fee payment |
Year of fee payment: 12 |
|
AS | Assignment |
Owner name: GOLDMAN SACHS BANK USA, NEW YORK Free format text: SECURITY AGREEMENT;ASSIGNORS:HOLOGIC, INC.;BIOLUCENT, LLC;CYTYC CORPORATION;AND OTHERS;REEL/FRAME:028810/0745 Effective date: 20120801 |
|
AS | Assignment |
Owner name: CYTYC SURGICAL PRODUCTS, LIMITED PARTNERSHIP, MASSACHUSETTS Free format text: SECURITY INTEREST RELEASE REEL/FRAME 028810/0745;ASSIGNOR:GOLDMAN SACHS BANK USA, AS COLLATERAL AGENT;REEL/FRAME:035820/0239 Effective date: 20150529 Owner name: CYTYC CORPORATION, MASSACHUSETTS Free format text: SECURITY INTEREST RELEASE REEL/FRAME 028810/0745;ASSIGNOR:GOLDMAN SACHS BANK USA, AS COLLATERAL AGENT;REEL/FRAME:035820/0239 Effective date: 20150529 Owner name: CYTYC SURGICAL PRODUCTS, LIMITED PARTNERSHIP, MASS Free format text: SECURITY INTEREST RELEASE REEL/FRAME 028810/0745;ASSIGNOR:GOLDMAN SACHS BANK USA, AS COLLATERAL AGENT;REEL/FRAME:035820/0239 Effective date: 20150529 Owner name: THIRD WAVE TECHNOLOGIES, INC., MASSACHUSETTS Free format text: SECURITY INTEREST RELEASE REEL/FRAME 028810/0745;ASSIGNOR:GOLDMAN SACHS BANK USA, AS COLLATERAL AGENT;REEL/FRAME:035820/0239 Effective date: 20150529 Owner name: SUROS SURGICAL SYSTEMS, INC., MASSACHUSETTS Free format text: SECURITY INTEREST RELEASE REEL/FRAME 028810/0745;ASSIGNOR:GOLDMAN SACHS BANK USA, AS COLLATERAL AGENT;REEL/FRAME:035820/0239 Effective date: 20150529 Owner name: BIOLUCENT, LLC, MASSACHUSETTS Free format text: SECURITY INTEREST RELEASE REEL/FRAME 028810/0745;ASSIGNOR:GOLDMAN SACHS BANK USA, AS COLLATERAL AGENT;REEL/FRAME:035820/0239 Effective date: 20150529 Owner name: HOLOGIC, INC., MASSACHUSETTS Free format text: SECURITY INTEREST RELEASE REEL/FRAME 028810/0745;ASSIGNOR:GOLDMAN SACHS BANK USA, AS COLLATERAL AGENT;REEL/FRAME:035820/0239 Effective date: 20150529 Owner name: GEN-PROBE INCORPORATED, MASSACHUSETTS Free format text: SECURITY INTEREST RELEASE REEL/FRAME 028810/0745;ASSIGNOR:GOLDMAN SACHS BANK USA, AS COLLATERAL AGENT;REEL/FRAME:035820/0239 Effective date: 20150529 |
|
AS | Assignment |
Owner name: CYTYC SURGICAL PRODUCTS, LIMITED PARTNERSHIP, MASSACHUSETTS Free format text: CORRECTIVE ASSIGNMENT TO CORRECT THE INCORRECT PATENT NO. 8081301 PREVIOUSLY RECORDED AT REEL: 035820 FRAME: 0239. ASSIGNOR(S) HEREBY CONFIRMS THE SECURITY INTEREST RELEASE;ASSIGNOR:GOLDMAN SACHS BANK USA, AS COLLATERAL AGENT;REEL/FRAME:044727/0529 Effective date: 20150529 Owner name: GOLDMAN SACHS BANK USA, NEW YORK Free format text: CORRECTIVE ASSIGNMENT TO CORRECT THE INCORRECT PATENT NO. 8081301 PREVIOUSLY RECORDED AT REEL: 028810 FRAME: 0745. ASSIGNOR(S) HEREBY CONFIRMS THE SECURITY AGREEMENT;ASSIGNORS:HOLOGIC, INC.;BIOLUCENT, LLC;CYTYC CORPORATION;AND OTHERS;REEL/FRAME:044432/0565 Effective date: 20120801 Owner name: HOLOGIC, INC., MASSACHUSETTS Free format text: CORRECTIVE ASSIGNMENT TO CORRECT THE INCORRECT PATENT NO. 8081301 PREVIOUSLY RECORDED AT REEL: 035820 FRAME: 0239. ASSIGNOR(S) HEREBY CONFIRMS THE SECURITY INTEREST RELEASE;ASSIGNOR:GOLDMAN SACHS BANK USA, AS COLLATERAL AGENT;REEL/FRAME:044727/0529 Effective date: 20150529 Owner name: BIOLUCENT, LLC, MASSACHUSETTS Free format text: CORRECTIVE ASSIGNMENT TO CORRECT THE INCORRECT PATENT NO. 8081301 PREVIOUSLY RECORDED AT REEL: 035820 FRAME: 0239. ASSIGNOR(S) HEREBY CONFIRMS THE SECURITY INTEREST RELEASE;ASSIGNOR:GOLDMAN SACHS BANK USA, AS COLLATERAL AGENT;REEL/FRAME:044727/0529 Effective date: 20150529 Owner name: GEN-PROBE INCORPORATED, MASSACHUSETTS Free format text: CORRECTIVE ASSIGNMENT TO CORRECT THE INCORRECT PATENT NO. 8081301 PREVIOUSLY RECORDED AT REEL: 035820 FRAME: 0239. ASSIGNOR(S) HEREBY CONFIRMS THE SECURITY INTEREST RELEASE;ASSIGNOR:GOLDMAN SACHS BANK USA, AS COLLATERAL AGENT;REEL/FRAME:044727/0529 Effective date: 20150529 Owner name: CYTYC CORPORATION, MASSACHUSETTS Free format text: CORRECTIVE ASSIGNMENT TO CORRECT THE INCORRECT PATENT NO. 8081301 PREVIOUSLY RECORDED AT REEL: 035820 FRAME: 0239. ASSIGNOR(S) HEREBY CONFIRMS THE SECURITY INTEREST RELEASE;ASSIGNOR:GOLDMAN SACHS BANK USA, AS COLLATERAL AGENT;REEL/FRAME:044727/0529 Effective date: 20150529 Owner name: THIRD WAVE TECHNOLOGIES, INC., MASSACHUSETTS Free format text: CORRECTIVE ASSIGNMENT TO CORRECT THE INCORRECT PATENT NO. 8081301 PREVIOUSLY RECORDED AT REEL: 035820 FRAME: 0239. ASSIGNOR(S) HEREBY CONFIRMS THE SECURITY INTEREST RELEASE;ASSIGNOR:GOLDMAN SACHS BANK USA, AS COLLATERAL AGENT;REEL/FRAME:044727/0529 Effective date: 20150529 Owner name: CYTYC SURGICAL PRODUCTS, LIMITED PARTNERSHIP, MASS Free format text: CORRECTIVE ASSIGNMENT TO CORRECT THE INCORRECT PATENT NO. 8081301 PREVIOUSLY RECORDED AT REEL: 035820 FRAME: 0239. ASSIGNOR(S) HEREBY CONFIRMS THE SECURITY INTEREST RELEASE;ASSIGNOR:GOLDMAN SACHS BANK USA, AS COLLATERAL AGENT;REEL/FRAME:044727/0529 Effective date: 20150529 Owner name: SUROS SURGICAL SYSTEMS, INC., MASSACHUSETTS Free format text: CORRECTIVE ASSIGNMENT TO CORRECT THE INCORRECT PATENT NO. 8081301 PREVIOUSLY RECORDED AT REEL: 035820 FRAME: 0239. ASSIGNOR(S) HEREBY CONFIRMS THE SECURITY INTEREST RELEASE;ASSIGNOR:GOLDMAN SACHS BANK USA, AS COLLATERAL AGENT;REEL/FRAME:044727/0529 Effective date: 20150529 |